Dr. Guilherme Loureiro Fracasso
Médico Psiquiatra · CRM-RS 36.500 | RQE 32.771

Base científica

Estudos, pesquisas e fontes principais que indicam nosso norte

As referências abaixo são pontos de apoio para a comunicação educativa desta página. Elas não substituem avaliação individual nem definem conduta isoladamente, mas são o norte da minha prática, que se apoia na Psiquiatria do Estilo de Vida, campo com diretriz clínica internacional (WFSBP/ASLM, 2023), meta-revisão em periódico de alto impacto (Firth et al., 2020) e consenso internacional recente sobre suas prioridades (Firth et al., 2025).

Sumário

Psiquiatria do Estilo de Vida

9 referências · 9 com link direto

  1. Firth J, et al. A meta-review of "lifestyle psychiatry": the role of exercise, smoking, diet and sleep in the prevention and treatment of mental disorders. World Psychiatry. 2020;19(3):360-380. doi:10.1002/wps.20773DOI 10.1002/wps.20773 (abre em nova aba)
  2. Singh B, et al. Effectiveness of physical activity interventions for improving depression, anxiety and distress: an overview of systematic reviews. Br J Sports Med. 2023;57(18):1203-1209. doi:10.1136/bjsports-2022-106195. PMID:36796860DOI 10.1136/bjsports-2022-106195 (abre em nova aba)
  3. Noetel M, et al. Effect of exercise for depression: systematic review and network meta-analysis of RCTs. BMJ. 2024;384:e075847. doi:10.1136/bmj-2023-075847. PMID:38355154DOI 10.1136/bmj-2023-075847 (abre em nova aba)
  4. Jacka FN, et al. A randomised controlled trial of dietary improvement for adults with major depression (the 'SMILES' trial). BMC Med. 2017;15:23. doi:10.1186/s12916-017-0791-yDOI 10.1186/s12916-017-0791-y (abre em nova aba)
  5. Sánchez-Villegas A, et al. Mediterranean diet-based intervention to improve depressive symptoms (PREDIDEP randomized trial). Nutr Neurosci. 2024. doi:10.1080/1028415X.2023.2283290 — ver também AMMEND (Bayes J, et al. Am J Clin Nutr. 2022).DOI 10.1080/1028415X.2023.2283290 (abre em nova aba)
  6. Effect of dietary interventions for depression and anxiety (médio a longo prazo): systematic review and meta-analysis. Ann Intern Med. 2025;178(7). doi:10.7326/ANNALS-24-03016DOI 10.7326/ANNALS-24-03016 (abre em nova aba)
  7. Piet J, Hougaard E. MBCT for prevention of relapse in recurrent major depressive disorder: systematic review and meta-analysis. Clin Psychol Rev. 2011;31(6):1032-1040. PMID:21802618. Cf. meta-análise de dados individuais, Nat Ment Health. 2023. doi:10.1038/s44220-023-00178-xDOI 10.1038/s44220-023-00178-x (abre em nova aba)
  8. Holt-Lunstad J, et al. Loneliness and social isolation as risk factors for mortality: a meta-analytic review. Perspect Psychol Sci. 2015;10(2):227-237. doi:10.1177/1745691614568352DOI 10.1177/1745691614568352 (abre em nova aba)
  9. Taylor GMJ, et al. Smoking cessation for improving mental health. Cochrane Database Syst Rev. 2021. doi:10.1002/14651858.CD013522.pub2. Cf. Taylor G, et al. BMJ. 2014;348:g1151. PMID:24524926DOI 10.1002/14651858.CD013522.pub2 (abre em nova aba)

Exercícios

203 referências · 52 com link direto

  1. Viña J, Sanchis-Gomar F, Martínez-Bello V, Gómez-Cabrera MC. Exercise acts as a drug; the pharmacological benefits of exercise. Br J Pharmacol. 2012;167(1):1-12. doi:10.1111/j.1476-5381.2012.01970.x. PMID: 22486393.DOI 10.1111/j.1476-5381.2012.01970.x (abre em nova aba)
  2. Pedersen BK, Saltin B. Exercise as medicine — evidence for prescribing exercise as therapy in 26 different chronic diseases. Scand J Med Sci Sports. 2015;25(Suppl 3):1-72. doi:10.1111/sms.12581. PMID: 26606383.DOI 10.1111/sms.12581 (abre em nova aba)
  3. Warburton DER, Nicol CW, Bredin SSD. Health benefits of physical activity: the evidence. CMAJ. 2006;174(6):801-809. doi:10.1503/cmaj.051351. PMID: 16534088.DOI 10.1503/cmaj.051351 (abre em nova aba)
  4. Lee IM, Shiroma EJ, Lobelo F, et al. Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy. Lancet. 2012;380(9838):219-229. PMID: 22818936.PMID 22818936 (abre em nova aba)
  5. Morris JN, Heady JA, Raffle PAB, et al. Coronary heart disease and physical activity of work. Lancet. 1953.
  6. Caspersen CJ, Powell KE, Christenson GM. Physical activity, exercise, and physical fitness: definitions and distinctions for health-related research. Public Health Rep. 1985.
  7. Pate RR, Pratt M, Blair SN, et al. Physical activity and public health: recommendation from the CDC and the ACSM. JAMA. 1995.
  8. Booth FW, Roberts CK, Laye MJ. Lack of exercise is a major cause of chronic diseases. Compr Physiol. 2012.
  9. Blair SN. Physical inactivity: the biggest public health problem of the 21st century. Br J Sports Med. 2009.
  10. Egan B, Zierath JR. Exercise metabolism and the molecular regulation of skeletal muscle adaptation. Cell Metab. 2013;17(2):162-184. doi:10.1016/j.cmet.2012.12.012. PMID: 23395166.DOI 10.1016/j.cmet.2012.12.012 (abre em nova aba)
  11. Hawley JA, Hargreaves M, Joyner MJ, Zierath JR. Integrative biology of exercise. Cell. 2014;159(4):738-749. doi:10.1016/j.cell.2014.10.029. PMID: 25417152.DOI 10.1016/j.cell.2014.10.029 (abre em nova aba)
  12. Holloszy JO. Biochemical adaptations in muscle: effects of exercise on mitochondrial oxygen uptake and respiratory enzyme activity in skeletal muscle. J Biol Chem. 1967;242(9):2278-2282. PMID: 4290225.PMID 4290225 (abre em nova aba)
  13. Coffey VG, Hawley JA. The molecular bases of training adaptation. Sports Med. 2007.
  14. Hargreaves M, Spriet LL. Skeletal muscle energy metabolism during exercise. Nat Metab. 2020.
  15. Hoppeler H, Flück M. Plasticity of skeletal muscle mitochondria: structure and function. Med Sci Sports Exerc. 2003.
  16. Atherton PJ, Smith K. Muscle protein synthesis in response to nutrition and exercise. J Physiol. 2012.
  17. Schoenfeld BJ. The mechanisms of muscle hypertrophy and their application to resistance training. J Strength Cond Res. 2010.
  18. Fyfe JJ, Bishop DJ, Stepto NK. Interference between concurrent resistance and endurance exercise. Sports Med. 2014.
  19. Holloszy JO, Coyle EF. Adaptations of skeletal muscle to endurance exercise and their metabolic consequences. J Appl Physiol. 1984.
  20. Hood DA, Memme JM, Oliveira AN, Triolo M. Maintenance of skeletal muscle mitochondria in health, exercise, and aging. Annu Rev Physiol. 2019.
  21. Bishop DJ, Granata C, Eynon N. Can we optimise the exercise training prescription to maximise improvements in mitochondria function and content? Biochim Biophys Acta. 2014.
  22. Ristow M, Zarse K, Oberbach A, et al. Antioxidants prevent health-promoting effects of physical exercise in humans. Proc Natl Acad Sci USA. 2009.
  23. Gomez-Cabrera MC, Domenech E, Viña J. Moderate exercise is an antioxidant: upregulation of antioxidant genes by training. Free Radic Biol Med. 2008.
  24. Little JP, Safdar A, Bishop D, et al. An acute bout of HIIT increases PGC-1α in human skeletal muscle. Am J Physiol Regul Integr Comp Physiol. 2011.
  25. Jornayvaz FR, Shulman GI. Regulation of mitochondrial biogenesis. Essays Biochem. 2010.
  26. Drake JC, Wilson RJ, Yan Z. Molecular mechanisms for mitochondrial adaptation to exercise training in skeletal muscle. FASEB J. 2016.
  27. Pedersen BK, Febbraio MA. Muscles, exercise and obesity: skeletal muscle as a secretory organ. Nat Rev Endocrinol. 2012;8(8):457-465. doi:10.1038/nrendo.2012.49. PMID: 22473333.DOI 10.1038/nrendo.2012.49 (abre em nova aba)
  28. Boström P, Wu J, Jedrychowski MP, et al. A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature. 2012;481(7382):463-468. doi:10.1038/nature10777. PMID: 22237023.DOI 10.1038/nature10777 (abre em nova aba)
  29. Wrann CD, White JP, Salogiannnis J, et al. Exercise induces hippocampal BDNF through a PGC-1α/FNDC5 pathway. Cell Metab. 2013;18(5):649-659. doi:10.1016/j.cmet.2013.09.008. PMID: 24120943.DOI 10.1016/j.cmet.2013.09.008 (abre em nova aba)
  30. Pedersen BK, Febbraio MA. Muscle as an endocrine organ: focus on muscle-derived interleukin-6. Physiol Rev. 2008.
  31. Moon HY, Becke A, Berron D, et al. Running-induced systemic cathepsin B secretion is associated with memory function. Cell Metab. 2016.
  32. Severinsen MCK, Pedersen BK. Muscle-organ crosstalk: the emerging roles of myokines. Endocr Rev. 2020.
  33. Whitham M, Febbraio MA. The ever-expanding myokinome: discovery challenges and therapeutic implications. Nat Rev Drug Discov. 2016.
  34. Karstoft K, Pedersen BK. Skeletal muscle as a gene regulatory endocrine organ. Curr Opin Clin Nutr Metab Care. 2016.
  35. Dinoff A, Herrmann N, Swardfager W, Lanctôt KL. The effect of acute exercise on blood concentrations of BDNF in healthy adults: a meta-analysis. Eur J Neurosci. 2017;46(1):1635-1646. doi:10.1111/ejn.13603. PMID: 28493624.DOI 10.1111/ejn.13603 (abre em nova aba)
  36. Erickson KI, Voss MW, Prakash RS, et al. Exercise training increases size of hippocampus and improves memory. Proc Natl Acad Sci USA. 2011;108(7):3017-3022. doi:10.1073/pnas.1015950108. PMID: 21282661.DOI 10.1073/pnas.1015950108 (abre em nova aba)
  37. Coen RF, et al. Failure to demonstrate that memory improvement is due either to aerobic exercise or increased hippocampal volume (carta). Proc Natl Acad Sci USA. 2011;108(18):E89. doi:10.1073/pnas.1102593108.DOI 10.1073/pnas.1102593108 (abre em nova aba)
  38. Cotman CW, Berchtold NC. Exercise: a behavioral intervention to enhance brain health and plasticity. Trends Neurosci. 2002.
  39. Vaynman S, Ying Z, Gomez-Pinilla F. Hippocampal BDNF mediates the efficacy of exercise on synaptic plasticity and cognition. Eur J Neurosci. 2004.
  40. Szuhany KL, Bugatti M, Otto MW. A meta-analytic review of the effects of exercise on brain-derived neurotrophic factor. J Psychiatr Res. 2015.
  41. Voss MW, Vivar C, Kramer AF, van Praag H. Bridging animal and human models of exercise-induced brain plasticity. Trends Cogn Sci. 2013.
  42. van Praag H, Christie BR, Sejnowski TJ, Gage FH. Running enhances neurogenesis, learning, and long-term potentiation in mice. Proc Natl Acad Sci USA. 1999.
  43. Colcombe S, Kramer AF. Fitness effects on the cognitive function of older adults: a meta-analytic study. Psychol Sci. 2003;14(2):125-130. doi:10.1111/1467-9280.t01-1-01430. PMID: 12661673.DOI 10.1111/1467-9280.t01-1-01430 (abre em nova aba)
  44. Northey JM, Cherbuin N, Pumpa KL, et al. Exercise interventions for cognitive function in adults older than 50: a systematic review with meta-analysis. Br J Sports Med. 2018;52(3):154-160. doi:10.1136/bjsports-2016-096587. PMID: 28438770.DOI 10.1136/bjsports-2016-096587 (abre em nova aba)
  45. Hillman CH, Erickson KI, Kramer AF. Be smart, exercise your heart: exercise effects on brain and cognition. Nat Rev Neurosci. 2008.
  46. Colcombe SJ, Erickson KI, Scalf PE, et al. Aerobic exercise training increases brain volume in aging humans. J Gerontol A Biol Sci Med Sci. 2006.
  47. Sofi F, Valecchi D, Bacci D, et al. Physical activity and risk of cognitive decline: a meta-analysis of prospective studies. J Intern Med. 2011.
  48. Erickson KI, Hillman C, Stillman CM, et al. Physical activity, cognition, and brain outcomes: a review of the 2018 PAG Advisory Committee. Med Sci Sports Exerc. 2019.
  49. Livingston G, Huntley J, Sommerlad A, et al. Dementia prevention, intervention, and care: 2020 Lancet Commission. Lancet. 2020.
  50. Hötting K, Röder B. Beneficial effects of physical exercise on neuroplasticity and cognition. Neurosci Biobehav Rev. 2013.
  51. Noetel M, Sanders T, Gallardo-Gómez D, et al. Effect of exercise for depression: systematic review and network meta-analysis of RCTs. BMJ. 2024;384:e075847. doi:10.1136/bmj-2023-075847. PMID: 38355154.DOI 10.1136/bmj-2023-075847 (abre em nova aba)
  52. Cooney GM, Dwan K, Greig CA, et al. Exercise for depression. Cochrane Database Syst Rev. 2013;(9):CD004366. doi:10.1002/14651858.CD004366.pub6. PMID: 24026850.DOI 10.1002/14651858.CD004366.pub6 (abre em nova aba)
  53. Gordon BR, McDowell CP, Hallgren M, et al. Association of efficacy of resistance exercise training with depressive symptoms: meta-analysis and meta-regression of RCTs. JAMA Psychiatry. 2018;75(6):566-576. doi:10.1001/jamapsychiatry.2018.0572. PMID: 29800984.DOI 10.1001/jamapsychiatry.2018.0572 (abre em nova aba)
  54. Schuch FB, Vancampfort D, Richards J, et al. Exercise as a treatment for depression: a meta-analysis adjusting for publication bias. J Psychiatr Res. 2016.
  55. Kvam S, Kleppe CL, Nordhus IH, Hovland A. Exercise as a treatment for depression: a meta-analysis. J Affect Disord. 2016.
  56. Krogh J, Hjorthøj C, Speyer H, et al. Exercise for patients with major depression: systematic review with meta-analysis. BMJ Open. 2017.
  57. Blumenthal JA, Babyak MA, Doraiswamy PM, et al. Exercise and pharmacotherapy in the treatment of major depressive disorder. Psychosom Med. 2007.
  58. Morres ID, Hatzigeorgiadis A, Stathi A, et al. Aerobic exercise for adult patients with major depression: meta-analysis. Depress Anxiety. 2019.
  59. Schuch FB, Vancampfort D, Firth J, et al. Physical activity and incident depression: a meta-analysis of prospective cohort studies. Am J Psychiatry. 2018;175(7):631-648. doi:10.1176/appi.ajp.2018.17111194. PMID: 29690792.DOI 10.1176/appi.ajp.2018.17111194 (abre em nova aba)
  60. Pearce M, Garcia L, Abbas A, et al. Association between physical activity and risk of depression: a systematic review and meta-analysis. JAMA Psychiatry. 2022;79(6):550-559. doi:10.1001/jamapsychiatry.2022.0609. PMID: 35416941.DOI 10.1001/jamapsychiatry.2022.0609 (abre em nova aba)
  61. Harvey SB, Øverland S, Hatch SL, et al. Exercise and the prevention of depression: results of the HUNT cohort study. Am J Psychiatry. 2018;175(1):28-36. doi:10.1176/appi.ajp.2017.16111223. PMID: 28969440.DOI 10.1176/appi.ajp.2017.16111223 (abre em nova aba)
  62. Choi KW, Chen CY, Stein MB, et al. Assessment of bidirectional relationships between physical activity and depression among adults: Mendelian randomization. JAMA Psychiatry. 2019.
  63. Chekroud SR, Gueorguieva R, Zheutlin AB, et al. Association between physical exercise and mental health in 1.2 million individuals in the USA: a cross-sectional study. Lancet Psychiatry. 2018;5(9):739-746. doi:10.1016/S2215-0366(18)30227-X. PMID: 30099000.DOI 10.1016/S2215-0366(18 (abre em nova aba)
  64. Stubbs B, Vancampfort D, Rosenbaum S, et al. An examination of the anxiolytic effects of exercise for people with anxiety and stress-related disorders: meta-analysis. Psychiatry Res. 2017.
  65. Gordon BR, McDowell CP, Lyons M, Herring MP. The effects of resistance exercise training on anxiety: meta-analysis. Sports Med. 2017.
  66. Wegner M, Helmich I, Machado S, et al. Effects of exercise on anxiety and depression disorders: review of meta-analyses. CNS Neurol Disord Drug Targets. 2014.
  67. Hackney AC. Stress and the neuroendocrine system: the role of exercise as a stressor. Expert Rev Endocrinol Metab. 2006.
  68. Kredlow MA, Capozzoli MC, Hearon BA, et al. The effects of physical activity on sleep: a meta-analytic review. J Behav Med. 2015.
  69. Stults-Kolehmainen MA, Sinha R. The effects of stress on physical activity and exercise. Sports Med. 2014.
  70. Kelley GA, Kelley KS. Exercise and sleep: a systematic review of previous meta-analyses. J Evid Based Med. 2017.
  71. Puterman E, Lin J, Blackburn E, et al. The power of exercise: buffering the effect of chronic stress on telomere length. PLoS One. 2010.
  72. Heijnen S, Hommel B, Kibele A, Colzato LS. Neuromodulation of aerobic exercise — a review. Front Psychol. 2016.
  73. Paffenbarger RS Jr, Hyde RT, Wing AL, Hsieh CC. Physical activity, all-cause mortality, and longevity of college alumni. N Engl J Med. 1986;314(10):605-613. doi:10.1056/NEJM198603063141003. PMID: 3945246.DOI 10.1056/NEJM198603063141003 (abre em nova aba)
  74. Wen CP, Wai JP, Tsai MK, et al. Minimum amount of physical activity for reduced mortality and extended life expectancy. Lancet. 2011;378(9798):1244-1253. doi:10.1016/S0140-6736(11)60749-6. PMID: 21846575.DOI 10.1016/S0140-6736(11 (abre em nova aba)
  75. Arem H, Moore SC, Patel A, et al. Leisure time physical activity and mortality: a detailed pooled analysis of the dose-response relationship. JAMA Intern Med. 2015;175(6):959-967. doi:10.1001/jamainternmed.2015.0533. PMID: 25844730.DOI 10.1001/jamainternmed.2015.0533 (abre em nova aba)
  76. Ekelund U, Tarp J, Steene-Johannessen J, et al. Dose-response associations between accelerometry measured physical activity and sedentary time and all cause mortality. BMJ. 2019;366:l4570. doi:10.1136/bmj.l4570. PMID: 31434697.DOI 10.1136/bmj.l4570 (abre em nova aba)
  77. Lee IM, Hsieh CC, Paffenbarger RS Jr. Exercise intensity and longevity in men: the Harvard Alumni Health Study. JAMA. 1995.
  78. Moore SC, Patel AV, Matthews CE, et al. Leisure time physical activity of moderate to vigorous intensity and mortality: a large pooled cohort analysis. PLoS Med. 2012.
  79. Arem H / Paffenbarger RS Jr, Hyde RT, Wing AL, et al. The association of changes in physical activity level and other lifestyle characteristics with mortality among men. N Engl J Med. 1993.
  80. Manson JE, Hu FB, Rich-Edwards JW, et al. Walking compared with vigorous exercise for the prevention of coronary events in women. N Engl J Med. 1999.
  81. Paluch AE, Bajpai S, Bassett DR, et al. (Steps for Health Collaborative). Daily steps and all-cause mortality: a meta-analysis of 15 international cohorts. Lancet Public Health. 2022;7(3):e219-e228. doi:10.1016/S2468-2667(21)00302-9. PMID: 35247352.DOI 10.1016/S2468-2667(21 (abre em nova aba)
  82. Saint-Maurice PF, Troiano RP, Bassett DR, et al. Association of daily step count and step intensity with mortality among US adults. JAMA. 2020;323(12):1151-1160. doi:10.1001/jama.2020.1382. PMID: 32207799.DOI 10.1001/jama.2020.1382 (abre em nova aba)
  83. Stamatakis E, Ahmadi MN, Gill JMR, et al. Association of wearable device-measured vigorous intermittent lifestyle physical activity with mortality. Nat Med. 2022;28(12):2521-2529. doi:10.1038/s41591-022-02100-x. PMID: 36482104.DOI 10.1038/s41591-022-02100-x (abre em nova aba)
  84. Lee IM, Shiroma EJ, Kamada M, et al. Association of step volume and intensity with all-cause mortality in older women. JAMA Intern Med. 2019.
  85. Paluch AE, Bajpai S, Ballin M, et al. Prospective association of daily steps with cardiovascular disease: a harmonized meta-analysis. Circulation. 2023.
  86. Banach M, Lewek J, Surma S, et al. The association between daily step count and all-cause and cardiovascular mortality: a meta-analysis. Eur J Prev Cardiol. 2023.
  87. Del Pozo Cruz B, Ahmadi MN, Lee IM, Stamatakis E. Prospective associations of daily step counts and intensity with cancer and CVD incidence and mortality. JAMA Intern Med. 2022.
  88. Jayedi A, Gohari A, Shab-Bidar S. Daily step count and all-cause mortality: a dose-response meta-analysis. Sports Med. 2022.
  89. Ross R, Blair SN, Arena R, et al. Importance of assessing cardiorespiratory fitness in clinical practice: a case for fitness as a clinical vital sign (AHA scientific statement). Circulation. 2016;134(24):e653-e699. doi:10.1161/CIR.0000000000000461. PMID: 27881567.DOI 10.1161/CIR.0000000000000461 (abre em nova aba)
  90. Kodama S, Saito K, Tanaka S, et al. Cardiorespiratory fitness as a quantitative predictor of all-cause mortality and cardiovascular events. JAMA. 2009;301(19):2024-2035. doi:10.1001/jama.2009.681. PMID: 19454641.DOI 10.1001/jama.2009.681 (abre em nova aba)
  91. Myers J, Prakash M, Froelicher V, et al. Exercise capacity and mortality among men referred for exercise testing. N Engl J Med. 2002;346(11):793-801. doi:10.1056/NEJMoa011858. PMID: 11893790.DOI 10.1056/NEJMoa011858 (abre em nova aba)
  92. Blair SN, Kohl HW 3rd, Paffenbarger RS Jr, et al. Physical fitness and all-cause mortality: a prospective study of healthy men and women. JAMA. 1989.
  93. Mandsager K, Harb S, Cremer P, et al. Association of cardiorespiratory fitness with long-term mortality among adults undergoing exercise treadmill testing. JAMA Netw Open. 2018.
  94. Kaminsky LA, Arena R, Myers J. Reference standards for cardiorespiratory fitness measured with cardiopulmonary exercise testing (FRIEND registry). Mayo Clin Proc. 2015.
  95. Harber MP, Kaminsky LA, Arena R, et al. Impact of cardiorespiratory fitness on all-cause and disease-specific mortality. Prog Cardiovasc Dis. 2017.
  96. Clausen JSR, Marott JL, Holtermann A, et al. Midlife cardiorespiratory fitness and the long-term risk of mortality. J Am Coll Cardiol. 2018.
  97. Leong DP, Teo KK, Rangarajan S, et al. Prognostic value of grip strength: findings from the PURE study. Lancet. 2015;386(9990):266-273. doi:10.1016/S0140-6736(14)62000-6. PMID: 25982160.DOI 10.1016/S0140-6736(14 (abre em nova aba)
  98. Celis-Morales CA, Welsh P, Lyall DM, et al. Associations of grip strength with cardiovascular, respiratory, and cancer outcomes and all cause mortality: UK Biobank. BMJ. 2018;361:k1651. doi:10.1136/bmj.k1651. PMID: 29739772.DOI 10.1136/bmj.k1651 (abre em nova aba)
  99. García-Hermoso A, Cavero-Redondo I, Ramírez-Vélez R, et al. Muscular strength as a predictor of all-cause mortality: systematic review and meta-analysis. Arch Phys Med Rehabil. 2018.
  100. Momma H, Kawakami R, Honda T, Sawada SS. Muscle-strengthening activities are associated with lower risk and mortality in major non-communicable diseases: meta-analysis. Br J Sports Med. 2022.
  101. Volaklis KA, Halle M, Meisinger C. Muscular strength as a strong predictor of mortality: a narrative review. Eur J Intern Med. 2015.
  102. Li R, Xia J, Zhang XI, et al. Associations of muscle mass and strength with all-cause mortality among US older adults. Med Sci Sports Exerc. 2018.
  103. Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis (EWGSOP2). Age Ageing. 2019.
  104. Fiatarone MA, O'Neill EF, Ryan ND, et al. Exercise training and nutritional supplementation for physical frailty in very elderly people. N Engl J Med. 1994;330(25):1769-1775. doi:10.1056/NEJM199406233302501. PMID: 8190152.DOI 10.1056/NEJM199406233302501 (abre em nova aba)
  105. Fiatarone MA, Marks EC, Ryan ND, et al. High-intensity strength training in nonagenarians: effects on skeletal muscle. JAMA. 1990.
  106. Peterson MD, Rhea MR, Sen A, Gordon PM. Resistance exercise for muscular strength in older adults: a meta-analysis. Ageing Res Rev. 2010.
  107. Pahor M, Guralnik JM, Ambrosius WT, et al. Effect of structured physical activity on prevention of major mobility disability in older adults (LIFE study). JAMA. 2014.
  108. Liu CJ, Latham NK. Progressive resistance strength training for improving physical function in older adults. Cochrane Database Syst Rev. 2009.
  109. Beaudart C, Dawson A, Shaw SC, et al. Nutrition and physical activity in the prevention and treatment of sarcopenia: systematic review. Osteoporos Int. 2017.
  110. Schoenfeld BJ, Grgic J, Ogborn D, Krieger JW. Strength and hypertrophy adaptations between low- vs high-load resistance training: meta-analysis. J Strength Cond Res. 2017.
  111. Suchomel TJ, Nimphius S, Stone MH. The importance of muscular strength in athletic performance. Sports Med. 2016.
  112. Knowler WC, Barrett-Connor E, Fowler SE, et al. (DPP). Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393-403. doi:10.1056/NEJMoa012512. PMID: 11832527.DOI 10.1056/NEJMoa012512 (abre em nova aba)
  113. Lean MEJ, Leslie WS, Barnes AC, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT). Lancet. 2018;391(10120):541-551. doi:10.1016/S0140-6736(17)33102-1. PMID: 29221645.DOI 10.1016/S0140-6736(17 (abre em nova aba)
  114. Boulé NG, Haddad E, Kenny GP, et al. Effects of exercise on glycemic control and body mass in type 2 diabetes: a meta-analysis. JAMA. 2001;286(10):1218-1227. doi:10.1001/jama.286.10.1218. PMID: 11559268.DOI 10.1001/jama.286.10.1218 (abre em nova aba)
  115. Colberg SR, Sigal RJ, Yardley JE, et al. Physical activity/exercise and diabetes: a position statement of the American Diabetes Association. Diabetes Care. 2016.
  116. Umpierre D, Ribeiro PAB, Kramer CK, et al. Physical activity advice only or structured exercise training and HbA1c levels in type 2 diabetes: meta-analysis. JAMA. 2011.
  117. Sigal RJ, Kenny GP, Boulé NG, et al. Effects of aerobic training, resistance training, or both on glycemic control in type 2 diabetes (DARE). Ann Intern Med. 2007.
  118. Tuomilehto J, Lindström J, Eriksson JG, et al. Prevention of type 2 diabetes by changes in lifestyle (Finnish DPS). N Engl J Med. 2001.
  119. Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM (Da Qing study). Diabetes Care. 1997.
  120. Cornelissen VA, Smart NA. Exercise training for blood pressure: a systematic review and meta-analysis. J Am Heart Assoc. 2013;2(1):e004473. doi:10.1161/JAHA.112.004473. PMID: 23525435.DOI 10.1161/JAHA.112.004473 (abre em nova aba)
  121. Anderson L, Oldridge N, Thompson DR, et al. Exercise-based cardiac rehabilitation for coronary heart disease: Cochrane systematic review and meta-analysis. J Am Coll Cardiol. 2016;67(1):1-12. doi:10.1016/j.jacc.2015.10.044. PMID: 26764059.DOI 10.1016/j.jacc.2015.10.044 (abre em nova aba)
  122. Naci H, Ioannidis JPA. Comparative effectiveness of exercise and drug interventions on mortality outcomes: metaepidemiological study. BMJ. 2013;347:f5577. doi:10.1136/bmj.f5577. PMID: 24149519.DOI 10.1136/bmj.f5577 (abre em nova aba)
  123. Pescatello LS, Franklin BA, Fagard R, et al. ACSM position stand: exercise and hypertension. Med Sci Sports Exerc. 2004.
  124. Thompson PD, Buchner D, Pina IL, et al. Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease (AHA). Circulation. 2003.
  125. Kraus WE, Houmard JA, Duscha BD, et al. Effects of the amount and intensity of exercise on plasma lipoproteins (STRRIDE). N Engl J Med. 2002.
  126. Sattelmair J, Pertman J, Ding EL, et al. Dose response between physical activity and risk of coronary heart disease: meta-analysis. Circulation. 2011.
  127. Pedralli ML, Marschner RA, Kollet DP, et al. Different exercise training modalities and endothelial function in hypertension: RCT. Sci Rep. 2020.
  128. Moore SC, Lee IM, Weiderpass E, et al. Association of leisure-time physical activity with risk of 26 types of cancer in 1.44 million adults. JAMA Intern Med. 2016;176(6):816-825. doi:10.1001/jamainternmed.2016.1548. PMID: 27183032.DOI 10.1001/jamainternmed.2016.1548 (abre em nova aba)
  129. Campbell KL, Winters-Stone KM, Wiskemann J, et al. Exercise guidelines for cancer survivors: consensus statement from international multidisciplinary roundtable. Med Sci Sports Exerc. 2019;51(11):2375-2390. doi:10.1249/MSS.0000000000002116. PMID: 31626055.DOI 10.1249/MSS.0000000000002116 (abre em nova aba)
  130. Schmitz KH, Campbell AM, Stuiver MM, et al. Exercise is medicine in oncology: engaging clinicians to help patients move through cancer. CA Cancer J Clin. 2019;69(6):468-484. doi:10.3322/caac.21579. PMID: 31617590.DOI 10.3322/caac.21579 (abre em nova aba)
  131. Schmitz KH, Courneya KS, Matthews C, et al. ACSM roundtable on exercise guidelines for cancer survivors. Med Sci Sports Exerc. 2010.
  132. Friedenreich CM, Neilson HK, Farris MS, Courneya KS. Physical activity and cancer outcomes: a precision medicine approach. Clin Cancer Res. 2016.
  133. McTiernan A, Friedenreich CM, Katzmarzyk PT, et al. Physical activity in cancer prevention and survival: a systematic review. Med Sci Sports Exerc. 2019.
  134. Christensen JF, Simonsen C, Hojman P. Exercise training in cancer control and treatment. Compr Physiol. 2018.
  135. Cormie P, Zopf EM, Zhang X, Schmitz KH. The impact of exercise on cancer mortality, recurrence, and treatment-related adverse effects. Epidemiol Rev. 2017.
  136. Howe TE, Shea B, Dawson LJ, et al. Exercise for preventing and treating osteoporosis in postmenopausal women. Cochrane Database Syst Rev. 2011.
  137. Watson SL, Weeks BK, Weis LJ, et al. High-intensity resistance and impact training improves bone mineral density (LIFTMOR RCT). J Bone Miner Res. 2018.
  138. Benedetti MG, Furlini G, Zati A, Letizia Mauro G. The effectiveness of physical exercise on bone density in osteoporotic patients. Biomed Res Int. 2018.
  139. Fransen M, McConnell S, Harmer AR, et al. Exercise for osteoarthritis of the knee. Cochrane Database Syst Rev. 2015.
  140. Beck BR, Daly RM, Singh MAF, Taaffe DR. Exercise and Sports Science Australia position statement on exercise prescription for the prevention of osteoporotic fractures. J Sci Med Sport. 2017.
  141. Hart NH, Newton RU, Tan J, et al. Biological basis of bone strength: anatomy, physiology and measurement. J Musculoskelet Neuronal Interact. 2020.
  142. Papadimitriou ID, Lucia A, Pitsiladis YP, et al. ACTN3 R577X and ACE I/D gene variants influence performance in elite sprinters: a multi-cohort study. BMC Genomics. 2016;17:285. doi:10.1186/s12864-016-2462-3. PMID: 27075997.DOI 10.1186/s12864-016-2462-3 (abre em nova aba)
  143. Bouchard C, An P, Rice T, et al. Familial aggregation of VO2max response to exercise training: results from the HERITAGE Family Study. J Appl Physiol. 1999;87(3):1003-1008. doi:10.1152/jappl.1999.87.3.1003. PMID: 10484570.DOI 10.1152/jappl.1999.87.3.1003 (abre em nova aba)
  144. Yang N, MacArthur DG, Gulbin JP, et al. ACTN3 genotype is associated with human elite athletic performance. Am J Hum Genet. 2003.
  145. Ahmetov II, Egorova ES, Gabdrakhmanova LJ, Fedotovskaya ON. Genes and athletic performance: an update. Med Sport Sci. 2016.
  146. Ma F, Yang Y, Li X, et al. The association of sport performance with ACE and ACTN3 gene polymorphisms: a systematic review and meta-analysis. PLoS One. 2013.
  147. Bouchard C, Sarzynski MA, Rice TK, et al. Genomic predictors of the maximal O2 uptake response to standardized exercise training. J Appl Physiol. 2011.
  148. Pickering C, Kiely J. ACTN3: more than just a gene for speed. Front Physiol. 2017.
  149. Sarzynski MA, Ghosh S, Bouchard C. Genomic and transcriptomic predictors of response levels to endurance exercise training. J Physiol. 2017.
  150. Gibala MJ, Little JP, MacDonald MJ, Hawley JA. Physiological adaptations to low-volume, high-intensity interval training in health and disease. J Physiol. 2012;590(5):1077-1084. doi:10.1113/jphysiol.2011.224725. PMID: 22289907.DOI 10.1113/jphysiol.2011.224725 (abre em nova aba)
  151. Weston KS, Wisløff U, Coombes JS. High-intensity interval training in patients with lifestyle-induced cardiometabolic disease: meta-analysis. Br J Sports Med. 2014.
  152. MacInnis MJ, Gibala MJ. Physiological adaptations to interval training and the role of exercise intensity. J Physiol. 2017.
  153. Milanović Z, Sporiš G, Weston M. Effectiveness of HIIT and continuous endurance training for VO2max improvements: meta-analysis. Sports Med. 2015.
  154. Wisløff U, Støylen A, Loennechen JP, et al. Superior cardiovascular effect of aerobic interval training versus moderate continuous training in heart failure. Circulation. 2007.
  155. San-Millán I, Brooks GA. Assessment of metabolic flexibility by means of measuring blood lactate, fat, and carbohydrate oxidation (Zona 2). Sports Med. 2018.
  156. Hickson RC. Interference of strength development by simultaneously training for strength and endurance. Eur J Appl Physiol. 1980.
  157. Murach KA, Bagley JR. Skeletal muscle hypertrophy with concurrent exercise training: contrary evidence for an interference effect. Sports Med. 2016.
  158. Bull FC, Al-Ansari SS, Biddle S, et al. World Health Organization 2020 guidelines on physical activity and sedentary behaviour. Br J Sports Med. 2020;54(24):1451-1462. doi:10.1136/bjsports-2020-102955. PMID: 33239350.DOI 10.1136/bjsports-2020-102955 (abre em nova aba)
  159. Piercy KL, Troiano RP, Ballard RM, et al. The physical activity guidelines for Americans. JAMA. 2018;320(19):2020-2028. doi:10.1001/jama.2018.14854. PMID: 30418471.DOI 10.1001/jama.2018.14854 (abre em nova aba)
  160. Garber CE, Blissmer B, Deschenes MR, et al. ACSM position stand: quantity and quality of exercise for developing and maintaining cardiorespiratory, musculoskeletal, and neuromotor fitness in apparently healthy adults. Med Sci Sports Exerc. 2011;43(7):1334-1359. doi:10.1249/MSS.0b013e318213fefb. PMID: 21694556.DOI 10.1249/MSS.0b013e318213fefb (abre em nova aba)
  161. 2018 Physical Activity Guidelines Advisory Committee. Scientific Report. US Dept Health Human Services. 2018.
  162. Haskell WL, Lee IM, Pate RR, et al. Physical activity and public health: updated recommendation for adults (ACSM/AHA). Med Sci Sports Exerc / Circulation. 2007.
  163. Thompson PD, Arena R, Riebe D, Pescatello LS. ACSM's new preparticipation health screening recommendations. Curr Sports Med Rep. 2013.
  164. Reiner M, Niermann C, Jekauc D, Woll A. Long-term health benefits of physical activity: a systematic review of longitudinal studies. BMC Public Health. 2013.
  165. Ding D, Lawson KD, Kolbe-Alexander TL, et al. The economic burden of physical inactivity: a global analysis. Lancet. 2016.
  166. Ornish D, Lin J, Chan JM, et al. Effect of comprehensive lifestyle changes on telomerase activity and telomere length in low-risk prostate cancer: 5-year follow-up. Lancet Oncol. 2013;14(11):1112-1120. doi:10.1016/S1470-2045(13)70366-8. PMID: 24051140.DOI 10.1016/S1470-2045(13 (abre em nova aba)
  167. Cherkas LF, Hunkin JL, Kato BS, et al. The association between physical activity in leisure time and leukocyte telomere length. Arch Intern Med. 2008.
  168. Gleeson M, Bishop NC, Stensel DJ, et al. The anti-inflammatory effects of exercise: mechanisms and implications. Nat Rev Immunol. 2011.
  169. Rebelo-Marques A, De Sousa Lages A, Andrade R, et al. Aging hallmarks: the benefits of physical exercise. Front Endocrinol. 2018.
  170. Garatachea N, Pareja-Galeano H, Sanchis-Gomar F, et al. Exercise attenuates the major hallmarks of aging. Rejuvenation Res. 2015.
  171. Rebelo-Marques A / Werner CM, Hecksteden A, Morsch A, et al. Differential effects of endurance, interval, and resistance training on telomerase activity. Eur Heart J. 2019.
  172. Duggal NA, Niemiro G, Harridge SDR, et al. Can physical activity ameliorate immunosenescence and thereby reduce age-related multimorbidity? Nat Rev Immunol. 2019.
  173. Sellami M, Gasmi M, Denham J, et al. Effects of acute and chronic exercise on immunological parameters in the elderly aged. Front Immunol. 2018.
  174. Lazarus NR, Harridge SDR. Declining performance of master athletes: silhouettes of the trajectory of healthy human ageing. J Physiol. 2017.
  175. Thompson PD, Franklin BA, Balady GJ, et al. Exercise and acute cardiovascular events: placing the risks into perspective (AHA). Circulation. 2007.
  176. ACOG Committee Opinion 804. Physical activity and exercise during pregnancy and the postpartum period. Obstet Gynecol. 2020.
  177. Pedersen BK. Physical activity and muscle-brain crosstalk. Nat Rev Endocrinol. 2019.
  178. Hötting K, Röder B / Stillman CM, Esteban-Cornejo I, Brown B, et al. Effects of exercise on brain and cognition across age groups and health states. Trends Neurosci. 2020.
  179. El-Sayes J, Harasym D, Turco CV, et al. Exercise-induced neuroplasticity: a mechanistic model. Neuroscientist. 2019.
  180. Mahalakshmi B, Maurya N, Lee SD, Bharath Kumar V. Possible neuroprotective mechanisms of physical exercise in neurodegeneration. Int J Mol Sci. 2020.
  181. Di Liegro CM, Schiera G, Proia P, Di Liegro I. Physical activity and brain health. Genes. 2019.
  182. Vivar C, Potter MC, van Praag H. All about running: synaptic plasticity, growth factors and adult hippocampal neurogenesis. Curr Top Behav Neurosci. 2013.
  183. Phillips C. Brain-derived neurotrophic factor, depression, and physical activity: making the neuroplastic connection. Neural Plast. 2017.
  184. Gabriel BM, Zierath JR. Circadian rhythms and exercise — re-setting the clock in metabolic disease. Nat Rev Endocrinol. 2019.
  185. Sato S, Basse AL, Schönke M, et al. Time of exercise specifies the impact on muscle metabolic pathways and systemic energy homeostasis. Cell Metab. 2019.
  186. Savikj M, Gabriel BM, Alm PS, et al. Afternoon exercise is more efficacious than morning exercise at improving blood glucose in type 2 diabetes. Diabetologia. 2019.
  187. Romijn JA, Coyle EF, Sidossis LS, et al. Regulation of endogenous fat and carbohydrate metabolism in relation to exercise intensity and duration. Am J Physiol. 1993.
  188. van Loon LJC, Greenhaff PL, Constantin-Teodosiu D, et al. The effects of increasing exercise intensity on muscle fuel utilisation in humans. J Physiol. 2001.
  189. Brooks GA. The science and translation of lactate shuttle theory. Cell Metab. 2018.
  190. Richter EA, Hargreaves M. Exercise, GLUT4, and skeletal muscle glucose uptake. Physiol Rev. 2013.
  191. Sylow L, Kleinert M, Richter EA, Jensen TE. Exercise-stimulated glucose uptake — regulation and implications for glycaemic control. Nat Rev Endocrinol. 2017.
  192. Donnelly JE, Blair SN, Jakicic JM, et al. ACSM position stand: appropriate physical activity intervention strategies for weight loss and prevention of weight regain. Med Sci Sports Exerc. 2009.
  193. Swift DL, Johannsen NM, Lavie CJ, et al. The role of exercise and physical activity in weight loss and maintenance. Prog Cardiovasc Dis. 2014.
  194. King NA, Hopkins M, Caudwell P, et al. Individual variability following 12 weeks of supervised exercise: identification and characterization of compensation for exercise-induced weight loss. Int J Obes. 2008.
  195. Pontzer H, Durazo-Arvizu R, Dugas LR, et al. Constrained total energy expenditure and metabolic adaptation to physical activity in adult humans. Curr Biol. 2016.
  196. Blundell JE, Gibbons C, Caudwell P, et al. Appetite control and energy balance: impact of exercise. Obes Rev. 2015.
  197. Jakicic JM, Rogers RJ, Davis KK, Collins KA. Role of physical activity and exercise in treating patients with overweight and obesity. Clin Chem. 2018.
  198. Willis LH, Slentz CA, Bateman LA, et al. Effects of aerobic and/or resistance training on body mass and fat mass in overweight adults (STRRIDE-AT/RT). J Appl Physiol. 2012.
  199. Ross R, Janssen I, Dawson J, et al. Exercise-induced reduction in obesity and insulin resistance in women: a randomized controlled trial. Obes Res. 2004.
  200. Foright RM, Presby DM, Sherk VD, et al. Is regular exercise an effective strategy for weight loss maintenance? Physiol Behav. 2018.
  201. Singh B, Olds T, Curtis R, et al. Effectiveness of physical activity interventions for improving depression, anxiety and distress: an overview of systematic reviews. Br J Sports Med. 2023;57(18):1203-1209. doi:10.1136/bjsports-2022-106195. PMID: 36796860.DOI 10.1136/bjsports-2022-106195 (abre em nova aba)
  202. Pearce M, Garcia L, Abbas A, et al. (ver item 60) — dose-resposta de prevenção: metade da dose −18%, dose plena −25%, fração atribuível 11,5%. JAMA Psychiatry. 2022.
  203. Noetel M, et al. (ver item 51) — efeitos por modalidade vs controle: caminhada/corrida g −0,62; ioga −0,55; força −0,49; comparadores TCC −0,55, ISRS −0,26. BMJ. 2024.

Alimentação

49 referências · 49 com link direto

  1. Gómez-Pinilla F. Brain foods: the effects of nutrients on brain function. Nat Rev Neurosci. 2008;9(7):568-578. doi:10.1038/nrn2421. PMID: 18568016. — Nutrientes modulam plasticidade/cognição; BDNF como elo central.DOI 10.1038/nrn2421 (abre em nova aba)
  2. Sarris J, Logan AC, Akbaraly TN, et al. Nutritional medicine as mainstream in psychiatry. Lancet Psychiatry. 2015;2(3):271-274. doi:10.1016/S2215-0366(14)00051-0. PMID: 26359904. — Position paper da ISNPR.DOI 10.1016/S2215-0366(14 (abre em nova aba)
  3. Jacka FN, O'Neil A, Opie R, et al. A randomised controlled trial of dietary improvement for adults with major depression (the 'SMILES' trial). BMC Med. 2017;15(1):23. doi:10.1186/s12916-017-0791-y. PMID: 28137247. — Dieta mediterrânea modificada melhora depressão; Cohen's d = −1,16.DOI 10.1186/s12916-017-0791-y (abre em nova aba)
  4. Marx W, Lane M, Hockey M, et al. Diet and depression: exploring the biological mechanisms of action. Mol Psychiatry. 2021;26(1):134-150. doi:10.1038/s41380-020-00925-x. PMID: 33144709. — Mecanismos: inflamação, oxidação, mitocôndria, microbiota, triptofano-quinurenina, HHA, BDNF.DOI 10.1038/s41380-020-00925-x (abre em nova aba)
  5. Firth J, Marx W, Dash S, et al. The effects of dietary improvement on symptoms of depression and anxiety: a meta-analysis of randomized controlled trials. Psychosom Med. 2019;81(3):265-280. doi:10.1097/PSY.0000000000000673. PMID: 30720698. — 16 RCTs; g = 0,275 (redução de sintomas depressivos).DOI 10.1097/PSY.0000000000000673 (abre em nova aba)
  6. Berk M, Williams LJ, Jacka FN, et al. So depression is an inflammatory disease, but where does the inflammation come from? BMC Med. 2013;11:200. doi:10.1186/1741-7015-11-200. PMID: 24228900. — Dieta, obesidade, permeabilidade intestinal, sono, vit D como fontes da inflamação.DOI 10.1186/1741-7015-11-200 (abre em nova aba)
  7. Liao Y, Xie B, Zhang H, et al. Efficacy of omega-3 PUFAs in depression: a meta-analysis. Transl Psychiatry. 2019;9(1):190. doi:10.1038/s41398-019-0515-5. PMID: 31383846. — 26 estudos; SMD = −0,28; efeito dirigido por EPA.DOI 10.1038/s41398-019-0515-5 (abre em nova aba)
  8. Adan RAH, van der Beek EM, Buitelaar JK, et al. Nutritional psychiatry: towards improving mental health by what you eat. Eur Neuropsychopharmacol. 2019;29(12):1321-1332. doi:10.1016/j.euroneuro.2019.10.011. PMID: 31735529.DOI 10.1016/j.euroneuro.2019.10.011 (abre em nova aba)
  9. Cryan JF, O'Riordan KJ, Cowan CSM, et al. The microbiota-gut-brain axis. Physiol Rev. 2019;99(4):1877-2013. doi:10.1152/physrev.00018.2018. PMID: 31460832. — Revisão-mãe da comunicação bidirecional.DOI 10.1152/physrev.00018.2018 (abre em nova aba)
  10. Dalile B, Van Oudenhove L, Vervliet B, Verbeke K. The role of short-chain fatty acids in microbiota-gut-brain communication. Nat Rev Gastroenterol Hepatol. 2019;16(8):461-478. doi:10.1038/s41575-019-0157-3. PMID: 31123355. — SCFAs (butirato) sinalizam ao cérebro.DOI 10.1038/s41575-019-0157-3 (abre em nova aba)
  11. Valles-Colomer M, Falony G, Darzi Y, et al. The neuroactive potential of the human gut microbiota in quality of life and depression. Nat Microbiol. 2019;4(4):623-632. doi:10.1038/s41564-018-0337-x. PMID: 30718848. — Coprococcus/Dialister depletados na depressão (n=1.054).DOI 10.1038/s41564-018-0337-x (abre em nova aba)
  12. Wastyk HC, Fragiadakis GK, Perelman D, et al. Gut-microbiota-targeted diets modulate human immune status. Cell. 2021;184(16):4137-4153.e14. doi:10.1016/j.cell.2021.06.019. PMID: 34256014. — Alimentos fermentados ↑ diversidade e ↓ 19 marcadores inflamatórios (RCT 17 sem).DOI 10.1016/j.cell.2021.06.019 (abre em nova aba)
  13. Sonnenburg ED, Sonnenburg JL. Starving our microbial self: the deleterious consequences of a diet deficient in microbiota-accessible carbohydrates. Cell Metab. 2014;20(5):779-786. doi:10.1016/j.cmet.2014.07.003. PMID: 25156449.DOI 10.1016/j.cmet.2014.07.003 (abre em nova aba)
  14. David LA, Maurice CF, Carmody RN, et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature. 2014;505(7484):559-563. doi:10.1038/nature12820. PMID: 24336217. — A dieta remodela a microbiota em ~1 dia.DOI 10.1038/nature12820 (abre em nova aba)
  15. Berding K, Vlckova K, Marx W, et al. Diet and the microbiota-gut-brain axis: sowing the seeds of good mental health. Adv Nutr. 2021;12(4):1239-1285. doi:10.1093/advances/nmaa181. PMID: 33693453.DOI 10.1093/advances/nmaa181 (abre em nova aba)
  16. Monteiro CA, Cannon G, Levy RB, et al. Ultra-processed foods: what they are and how to identify them. Public Health Nutr. 2019;22(5):936-941. doi:10.1017/S1368980018003762. PMID: 30744710. — Definição NOVA Grupo 4.DOI 10.1017/S1368980018003762 (abre em nova aba)
  17. Hall KD, Ayuketah A, Brychta R, et al. Ultra-processed diets cause excess calorie intake and weight gain: an inpatient randomized controlled trial of ad libitum food intake. Cell Metab. 2019;30(1):67-77.e3. doi:10.1016/j.cmet.2019.05.008. PMID: 31105044. — UPF → +~500 kcal/dia e +0,9 kg/2 sem (dietas pareadas).DOI 10.1016/j.cmet.2019.05.008 (abre em nova aba)
  18. Srour B, Fezeu LK, Kesse-Guyot E, et al. Ultra-processed food intake and risk of cardiovascular disease: prospective cohort study (NutriNet-Santé). BMJ. 2019;365:l1451. doi:10.1136/bmj.l1451. PMID: 31142457. — +10% UPF → HR CV 1,12 (n=105.159).DOI 10.1136/bmj.l1451 (abre em nova aba)
  19. Lane MM, Gamage E, Du S, et al. Ultra-processed food exposure and adverse health outcomes: umbrella review of epidemiological meta-analyses. BMJ. 2024;384:e077310. doi:10.1136/bmj-2023-077310. PMID: 38418082. — 45 análises, ~9,9M; mortalidade, CV, transtornos mentais, obesidade.DOI 10.1136/bmj-2023-077310 (abre em nova aba)
  20. Lane MM, Davis JA, Beattie S, et al. Ultraprocessed food and chronic noncommunicable diseases: a systematic review and meta-analysis of 43 observational studies. Obes Rev. 2021;22(3):e13146. doi:10.1111/obr.13146. PMID: 33167080. — Depressão entre os desfechos adultos (n=891.723).DOI 10.1111/obr.13146 (abre em nova aba)
  21. Chassaing B, Koren O, Goodrich JK, et al. Dietary emulsifiers impact the mouse gut microbiota promoting colitis and metabolic syndrome. Nature. 2015;519(7541):92-96. doi:10.1038/nature14232. PMID: 25731162. — CMC/polissorbato-80 → inflamação e síndrome metabólica.DOI 10.1038/nature14232 (abre em nova aba)
  22. Suez J, Korem T, Zeevi D, et al. Artificial sweeteners induce glucose intolerance by altering the gut microbiota. Nature. 2014;514(7521):181-186. doi:10.1038/nature13793. PMID: 25231862.DOI 10.1038/nature13793 (abre em nova aba)
  23. Gearhardt AN, Corbin WR, Brownell KD. Preliminary validation of the Yale Food Addiction Scale. Appetite. 2009;52(2):430-436. doi:10.1016/j.appet.2008.12.003. PMID: 19121351.DOI 10.1016/j.appet.2008.12.003 (abre em nova aba)
  24. Morris MC, Tangney CC, Wang Y, et al. MIND diet associated with reduced incidence of Alzheimer's disease. Alzheimers Dement. 2015;11(9):1007-1014. doi:10.1016/j.jalz.2014.11.009. PMID: 25681666. — Alta adesão HR 0,47 (~53% ↓); moderada HR 0,65 (~35% ↓). Observacional.DOI 10.1016/j.jalz.2014.11.009 (abre em nova aba)
  25. Morris MC, Tangney CC, Wang Y, et al. MIND diet slows cognitive decline with aging. Alzheimers Dement. 2015;11(9):1015-1022. doi:10.1016/j.jalz.2015.04.011. PMID: 26086182. — Equivalente a ~7,5 anos mais jovem na cognição.DOI 10.1016/j.jalz.2015.04.011 (abre em nova aba)
  26. Valls-Pedret C, Sala-Vila A, Serra-Mir M, et al. Mediterranean diet and age-related cognitive decline: a randomized clinical trial. JAMA Intern Med. 2015;175(7):1094-1103. doi:10.1001/jamainternmed.2015.1668. PMID: 25961184.DOI 10.1001/jamainternmed.2015.1668 (abre em nova aba)
  27. Scarmeas N, Anastasiou CA, Yannakoulia M. Nutrition and prevention of cognitive impairment. Lancet Neurol. 2018;17(11):1006-1015. doi:10.1016/S1474-4422(18)30338-7. PMID: 30244829.DOI 10.1016/S1474-4422(18 (abre em nova aba)
  28. Neal EG, Chaffe H, Schwartz RH, et al. The ketogenic diet for the treatment of childhood epilepsy: a randomised controlled trial. Lancet Neurol. 2008;7(6):500-506. doi:10.1016/S1474-4422(08)70092-9. PMID: 18456557. — Indicação estabelecida (epilepsia refratária).DOI 10.1016/S1474-4422(08 (abre em nova aba)
  29. Sethi S, Wakeham D, Ketter T, et al. Ketogenic diet intervention on metabolic and psychiatric health in bipolar and schizophrenia: a pilot trial. Psychiatry Res. 2024;335:115866. doi:10.1016/j.psychres.2024.115866. PMID: 38547601. — Piloto Stanford; sinal metabólico+psiquiátrico (n pequeno, sem controle).DOI 10.1016/j.psychres.2024.115866 (abre em nova aba)
  30. Brietzke E, Mansur RB, Subramaniapillai M, et al. Ketogenic diet as a metabolic therapy for mood disorders: evidence and developments. Neurosci Biobehav Rev. 2018;94:11-16. doi:10.1016/j.neubiorev.2018.07.020. PMID: 30075165.DOI 10.1016/j.neubiorev.2018.07.020 (abre em nova aba)
  31. Phillips MCL, Deprez LM, Mortimer GMN, et al. Randomized crossover trial of a modified ketogenic diet in Alzheimer's disease. Alzheimers Res Ther. 2021;13(1):51. doi:10.1186/s13195-021-00783-x. PMID: 33622392.DOI 10.1186/s13195-021-00783-x (abre em nova aba)
  32. Norwitz NG, Feldman D, Soto-Mota A, et al. Elevated LDL cholesterol with a carbohydrate-restricted diet: evidence for a "lean mass hyper-responder" phenotype. Curr Dev Nutr. 2022;6(1):nzab144. doi:10.1093/cdn/nzab144. PMID: 35106434. — Caveat lipídico de keto/low-carb (LDL ≥200 em subgrupo); crítica publicada.DOI 10.1093/cdn/nzab144 (abre em nova aba)
  33. Bhanpuri NH, Hallberg SJ, Williams PT, et al. Cardiovascular disease risk factor responses to a type 2 diabetes care model including nutritional ketosis at 1 year (Virta). Cardiovasc Diabetol. 2018;17(1):56. doi:10.1186/s12933-018-0698-8. PMID: 29712560.DOI 10.1186/s12933-018-0698-8 (abre em nova aba)
  34. Lennerz BS, Mey JT, Henn OH, Ludwig DS. Behavioral characteristics and self-reported health status among 2029 adults consuming a "carnivore diet". Curr Dev Nutr. 2021;5(12):nzab133. doi:10.1093/cdn/nzab133. PMID: 34934897. — Único dado de porte; autorrelato, sem verificação clínica.DOI 10.1093/cdn/nzab133 (abre em nova aba)
  35. Sutton EF, Beyl R, Early KS, et al. Early time-restricted feeding improves insulin sensitivity, blood pressure, and oxidative stress even without weight loss in men with prediabetes. Cell Metab. 2018;27(6):1212-1221.e3. doi:10.1016/j.cmet.2018.04.010. PMID: 29754952.DOI 10.1016/j.cmet.2018.04.010 (abre em nova aba)
  36. Wilkinson MJ, Manoogian ENC, Zadourian A, et al. Ten-hour time-restricted eating reduces weight, blood pressure, and atherogenic lipids in patients with metabolic syndrome. Cell Metab. 2020;31(1):92-104.e5. doi:10.1016/j.cmet.2019.11.004. PMID: 31813824.DOI 10.1016/j.cmet.2019.11.004 (abre em nova aba)
  37. Scheer FAJL, Hilton MF, Mantzoros CS, Shea SA. Adverse metabolic and cardiovascular consequences of circadian misalignment. Proc Natl Acad Sci USA. 2009;106(11):4453-4458. doi:10.1073/pnas.0808180106. PMID: 19255424.DOI 10.1073/pnas.0808180106 (abre em nova aba)
  38. Manoogian ENC, Chow LS, Taub PR, Laferrère B, Panda S. Time-restricted eating for the prevention and management of metabolic diseases. Endocr Rev. 2022;43(2):405-436. doi:10.1210/endrev/bnab027. PMID: 34550357.DOI 10.1210/endrev/bnab027 (abre em nova aba)
  39. Jamshed H, Steger FL, Bryan DR, et al. Effectiveness of early time-restricted eating for weight loss, fat loss, and cardiometabolic health in adults with obesity: the TREAT randomized clinical trial. JAMA Intern Med. 2022;182(9):953-962. doi:10.1001/jamainternmed.2022.3050. PMID: 35939311. — eTRF (7–15h) + restrição: positivo.DOI 10.1001/jamainternmed.2022.3050 (abre em nova aba)
  40. Chaix A, Manoogian ENC, Melkani GC, Panda S. Time-restricted eating to prevent and manage chronic metabolic diseases. Annu Rev Nutr. 2019;39:291-315. doi:10.1146/annurev-nutr-082018-124320. PMID: 31180809.DOI 10.1146/annurev-nutr-082018-124320 (abre em nova aba)
  41. Jakubowicz D, Barnea M, Wainstein J, Froy O. High caloric intake at breakfast vs. dinner differentially influences weight loss of overweight and obese women. Obesity (Silver Spring). 2013;21(12):2504-2512. doi:10.1002/oby.20460. PMID: 23512957.DOI 10.1002/oby.20460 (abre em nova aba)
  42. Afshin A, et al; GBD 2017 Diet Collaborators. Health effects of dietary risks in 195 countries, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2019;393(10184):1958-1972. doi:10.1016/S0140-6736(19)30041-8. PMID: 30954305. — ~11 mi mortes/ano por riscos dietéticos; sódio, grão integral e fruta dominam.DOI 10.1016/S0140-6736(19 (abre em nova aba)
  43. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: network meta-analysis. Lancet. 2018;391(10128):1357-1366. doi:10.1016/S0140-6736(17)32802-7. PMID: 29477251. — antidepressivos vs placebo OR ~1,37–2,13 (sumário ~1,65); âncora de comparação (o "SMD ~0,3" é conversão externa, não reportada no paper).DOI 10.1016/S0140-6736(17 (abre em nova aba)
  44. Li Y, Pan A, Wang DD, et al. Impact of healthy lifestyle factors on life expectancies in the US population. Circulation. 2018;138(4):345-355. doi:10.1161/CIRCULATIONAHA.117.032047. PMID: 29712712. — 5 fatores (incl. dieta) → +14 anos (mulher) / +12,2 (homem) aos 50.DOI 10.1161/CIRCULATIONAHA.117.032047 (abre em nova aba)
  45. Vilar-Gómez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015;149(2):367-378.e5. doi:10.1053/j.gastro.2015.04.005. PMID: 25865049. — ≥10% de perda de peso → 90% resolução de NASH, 45% regressão de fibrose.DOI 10.1053/j.gastro.2015.04.005 (abre em nova aba)
  46. Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pressure of reduced dietary sodium and the DASH diet (DASH-Sodium). N Engl J Med. 2001;344(1):3-10. doi:10.1056/NEJM200101043440101. PMID: 11136953. — DASH + baixo sódio: PA sistólica −11,5 mmHg (hipertensos).DOI 10.1056/NEJM200101043440101 (abre em nova aba)
  47. Vockley J, Andersson HC, Antshel KM, et al. Phenylalanine hydroxylase deficiency: diagnosis and management guideline. Genet Med. 2014;16(2):188-200. doi:10.1038/gim.2013.157. PMID: 24385074. — diretriz ACMG; restrição de Phe (120–360 µmol/L) é a terapia da PKU.DOI 10.1038/gim.2013.157 (abre em nova aba)
  48. Kossoff EH, Zupec-Kania BA, Auvin S, et al. Optimal clinical management of children receiving dietary therapies for epilepsy: updated recommendations of the International Ketogenic Diet Study Group. Epilepsia Open. 2018;3(2):175-192. doi:10.1002/epi4.12225. PMID: 29881797. — consenso: cetogênica como terapia estabelecida na epilepsia refratária.DOI 10.1002/epi4.12225 (abre em nova aba)
  49. Schwingshackl L, Schwedhelm C, Hoffmann G, et al. Food groups and risk of all-cause mortality: a systematic review and meta-analysis of prospective studies. Am J Clin Nutr. 2017;105(6):1462-1473. doi:10.3945/ajcn.117.153148. PMID: 28446499. — por porção: grão integral RR 0,92; carne processada RR 1,23.DOI 10.3945/ajcn.117.153148 (abre em nova aba)

Sono Restaurador

77 referências · 76 com link direto

  1. Borbély AA. A two process model of sleep regulation. Hum Neurobiol. 1982;1(3):195-204. PMID: 7185792.PMID 7185792 (abre em nova aba)
  2. Dijk DJ, Czeisler CA. Contribution of the circadian pacemaker and the sleep homeostat to sleep propensity, sleep structure, electroencephalographic slow waves, and sleep spindle activity in humans. J Neurosci. 1995;15(5):3526-3538. doi:10.1523/JNEUROSCI.15-05-03526.1995. PMID: 7751928.DOI 10.1523/JNEUROSCI.15-05-03526.1995 (abre em nova aba)
  3. Tononi G, Cirelli C. Sleep and synaptic homeostasis: a hypothesis. Brain Res Bull. 2003;62(2):143-150. doi:10.1016/j.brainresbull.2003.09.004. PMID: 14638388.DOI 10.1016/j.brainresbull.2003.09.004 (abre em nova aba)
  4. Tononi G, Cirelli C. Sleep function and synaptic homeostasis. Sleep Med Rev. 2006;10(1):49-62. doi:10.1016/j.smrv.2005.05.002. PMID: 16376591.DOI 10.1016/j.smrv.2005.05.002 (abre em nova aba)
  5. Diekelmann S, Born J. The memory function of sleep. Nat Rev Neurosci. 2010;11(2):114-126. doi:10.1038/nrn2762. PMID: 20046194.DOI 10.1038/nrn2762 (abre em nova aba)
  6. Rasch B, Born J. About sleep's role in memory. Physiol Rev. 2013;93(2):681-766. doi:10.1152/physrev.00032.2012. PMID: 23589831.DOI 10.1152/physrev.00032.2012 (abre em nova aba)
  7. Walker MP, van der Helm E. Overnight therapy? The role of sleep in emotional brain processing. Psychol Bull. 2009;135(5):731-748. doi:10.1037/a0016570. PMID: 19702380.DOI 10.1037/a0016570 (abre em nova aba)
  8. Goldstein AN, Walker MP. The role of sleep in emotional brain function. Annu Rev Clin Psychol. 2014;10:679-708. doi:10.1146/annurev-clinpsy-032813-153716. PMID: 24499013.DOI 10.1146/annurev-clinpsy-032813-153716 (abre em nova aba)
  9. Walker MP. The role of sleep in cognition and emotion. Ann N Y Acad Sci. 2009;1156:168-197. doi:10.1111/j.1749-6632.2009.04416.x. PMID: 19338508.DOI 10.1111/j.1749-6632.2009.04416.x (abre em nova aba)
  10. Iliff JJ, Wang M, Liao Y, et al. A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid β. Sci Transl Med. 2012;4(147):147ra111. doi:10.1126/scitranslmed.3003748. PMID: 22896675.DOI 10.1126/scitranslmed.3003748 (abre em nova aba)
  11. Xie L, Kang H, Xu Q, et al. Sleep drives metabolite clearance from the adult brain. Science. 2013;342(6156):373-377. doi:10.1126/science.1241224. PMID: 24136970.DOI 10.1126/science.1241224 (abre em nova aba)
  12. Shokri-Kojori E, Wang GJ, Wiers CE, et al. β-Amyloid accumulation in the human brain after one night of sleep deprivation. Proc Natl Acad Sci USA. 2018;115(17):4483-4488. doi:10.1073/pnas.1721694115. PMID: 29632177.DOI 10.1073/pnas.1721694115 (abre em nova aba)
  13. Nedergaard M, Goldman SA. Glymphatic failure as a final common pathway to dementia. Science. 2020;370(6512):50-56. doi:10.1126/science.abb8739. PMID: 33004510.DOI 10.1126/science.abb8739 (abre em nova aba)
  14. Osorio RS, Gumb T, Pirraglia E, et al. Sleep-disordered breathing advances cognitive decline in the elderly. Neurology. 2015;84(19):1964-1971. doi:10.1212/WNL.0000000000001566. PMID: 25878183.DOI 10.1212/WNL.0000000000001566 (abre em nova aba)
  15. Irwin M, McClintick J, Costlow C, et al. Partial night sleep deprivation reduces natural killer and cellular immune responses in humans. FASEB J. 1996;10(5):643-653. doi:10.1096/fasebj.10.5.8621064. PMID: 8621064.DOI 10.1096/fasebj.10.5.8621064 (abre em nova aba)
  16. Jones SE, Lane JM, Wood AR, et al. Genome-wide association analyses of chronotype in 697,828 individuals provides insights into circadian rhythms. Nat Commun. 2019;10(1):343. doi:10.1038/s41467-018-08259-7. PMID: 30696823.DOI 10.1038/s41467-018-08259-7 (abre em nova aba)
  17. Hu Y, Shmygelska A, Tran D, et al. GWAS of 89,283 individuals identifies genetic variants associated with self-reporting of being a morning person. Nat Commun. 2016;7:10448. doi:10.1038/ncomms10448. PMID: 26835600.DOI 10.1038/ncomms10448 (abre em nova aba)
  18. Roenneberg T, Allebrandt KV, Merrow M, Vetter C. Social jetlag and obesity. Curr Biol. 2012;22(10):939-943. doi:10.1016/j.cub.2012.03.038. PMID: 22578422.DOI 10.1016/j.cub.2012.03.038 (abre em nova aba)
  19. Wittmann M, Dinich J, Merrow M, Roenneberg T. Social jetlag: misalignment of biological and social time. Chronobiol Int. 2006;23(1-2):497-509. doi:10.1080/07420520500545979. PMID: 16687322.DOI 10.1080/07420520500545979 (abre em nova aba)
  20. Roenneberg T, Wirz-Justice A, Merrow M. Life between clocks: daily temporal patterns of human chronotypes. J Biol Rhythms. 2003;18(1):80-90. doi:10.1177/0748730402239679. PMID: 12568247.DOI 10.1177/0748730402239679 (abre em nova aba)
  21. Czeisler CA, Duffy JF, Shanahan TL, et al. Stability, precision, and near-24-hour period of the human circadian pacemaker. Science. 1999;284(5423):2177-2181. doi:10.1126/science.284.5423.2177. PMID: 10381883.DOI 10.1126/science.284.5423.2177 (abre em nova aba)
  22. Khalsa SBS, Jewett ME, Cajochen C, Czeisler CA. A phase response curve to single bright light pulses in human subjects. J Physiol. 2003;549(Pt 3):945-952. doi:10.1113/jphysiol.2003.040477. PMID: 12717008.DOI 10.1113/jphysiol.2003.040477 (abre em nova aba)
  23. Chang AM, Aeschbach D, Duffy JF, Czeisler CA. Evening use of light-emitting eReaders negatively affects sleep, circadian timing, and next-morning alertness. Proc Natl Acad Sci USA. 2015;112(4):1232-1237. doi:10.1073/pnas.1418490112. PMID: 25535358.DOI 10.1073/pnas.1418490112 (abre em nova aba)
  24. Gooley JJ, Chamberlain K, Smith KA, et al. Exposure to room light before bedtime suppresses melatonin onset and shortens melatonin duration in humans. J Clin Endocrinol Metab. 2011;96(3):E463-E472. doi:10.1210/jc.2010-2098. PMID: 21193540.DOI 10.1210/jc.2010-2098 (abre em nova aba)
  25. Brown SA, Kunz D, Dumas A, et al. Molecular insights into human daily behavior. Proc Natl Acad Sci USA. 2008;105(5):1602-1607. doi:10.1073/pnas.0707772105. PMID: 18227513.DOI 10.1073/pnas.0707772105 (abre em nova aba)
  26. Takahashi JS. Transcriptional architecture of the mammalian circadian clock. Nat Rev Genet. 2017;18(3):164-179. doi:10.1038/nrg.2016.150. PMID: 27990019.DOI 10.1038/nrg.2016.150 (abre em nova aba)
  27. Toh KL, Jones CR, He Y, et al. An hPer2 phosphorylation site mutation in familial advanced sleep phase syndrome. Science. 2001;291(5506):1040-1043. doi:10.1126/science.1057499. PMID: 11232563.DOI 10.1126/science.1057499 (abre em nova aba)
  28. Patke A, Murphy PJ, Onat OE, et al. Mutation of the human circadian clock gene CRY1 in familial delayed sleep phase disorder. Cell. 2017;169(2):203-215.e13. doi:10.1016/j.cell.2017.03.027. PMID: 28388406.DOI 10.1016/j.cell.2017.03.027 (abre em nova aba)
  29. He Y, Jones CR, Fujiki N, et al. The transcriptional repressor DEC2 regulates sleep length in mammals. Science. 2009;325(5942):866-870. doi:10.1126/science.1174443. PMID: 19679812.DOI 10.1126/science.1174443 (abre em nova aba)
  30. Archer SN, Robilliard DL, Skene DJ, et al. A length polymorphism in the circadian clock gene Per3 is linked to delayed sleep phase syndrome and extreme diurnal preference. Sleep. 2003;26(4):413-415. doi:10.1093/sleep/26.4.413. PMID: 12841365.DOI 10.1093/sleep/26.4.413 (abre em nova aba)
  31. Saper CB, Scammell TE, Lu J. Hypothalamic regulation of sleep and circadian rhythms. Nature. 2005;437(7063):1257-1263. doi:10.1038/nature04284. PMID: 16251950.DOI 10.1038/nature04284 (abre em nova aba)
  32. de Lecea L, Kilduff TS, Peyron C, et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci USA. 1998;95(1):322-327. doi:10.1073/pnas.95.1.322. PMID: 9419374.DOI 10.1073/pnas.95.1.322 (abre em nova aba)
  33. Scammell TE. Narcolepsy. N Engl J Med. 2015;373(27):2654-2662. doi:10.1056/NEJMra1500587. PMID: 26716917.DOI 10.1056/NEJMra1500587 (abre em nova aba)
  34. Li L, Wu C, Gan Y, Qu X, Lu Z. Insomnia and the risk of depression: a meta-analysis of prospective cohort studies. BMC Psychiatry. 2016;16:375. doi:10.1186/s12888-016-1075-3. PMID: 27816065.DOI 10.1186/s12888-016-1075-3 (abre em nova aba)
  35. Baglioni C, Battagliese G, Feige B, et al. Insomnia as a predictor of depression: a meta-analytic evaluation of longitudinal epidemiological studies. J Affect Disord. 2011;135(1-3):10-19. doi:10.1016/j.jad.2011.01.011. PMID: 21300408.DOI 10.1016/j.jad.2011.01.011 (abre em nova aba)
  36. Trauer JM, Qian MY, Doyle JS, Rajaratnam SMW, Cunnington D. Cognitive behavioral therapy for chronic insomnia: a systematic review and meta-analysis. Ann Intern Med. 2015;163(3):191-204. doi:10.7326/M14-2841. PMID: 26054060.DOI 10.7326/M14-2841 (abre em nova aba)
  37. Qaseem A, Kansagara D, Forciea MA, et al. Management of chronic insomnia disorder in adults: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2016;165(2):125-133. doi:10.7326/M15-2175. PMID: 27136449.DOI 10.7326/M15-2175 (abre em nova aba)
  38. Riemann D, Baglioni C, Bassetti C, et al. European guideline for the diagnosis and treatment of insomnia. J Sleep Res. 2017;26(6):675-700. doi:10.1111/jsr.12594. PMID: 28875581.DOI 10.1111/jsr.12594 (abre em nova aba)
  39. Riemann D, Espie CA, Altena E, et al. The European Insomnia Guideline: an update on the diagnosis and treatment of insomnia 2023. J Sleep Res. 2023;32(6):e14035. doi:10.1111/jsr.14035. PMID: 38016484.DOI 10.1111/jsr.14035 (abre em nova aba)
  40. Riemann D, Spiegelhalder K, Feige B, et al. The hyperarousal model of insomnia: a review of the concept and its evidence. Sleep Med Rev. 2010;14(1):19-31. doi:10.1016/j.smrv.2009.04.002. PMID: 19481481.DOI 10.1016/j.smrv.2009.04.002 (abre em nova aba)
  41. Bonnet MH, Arand DL. Hyperarousal and insomnia: state of the science. Sleep Med Rev. 2010;14(1):9-15. doi:10.1016/j.smrv.2009.05.002. PMID: 19640748.DOI 10.1016/j.smrv.2009.05.002 (abre em nova aba)
  42. Perlis ML, Giles DE, Mendelson WB, Bootzin RR, Wyatt JK. Psychophysiological insomnia: the behavioural model and a neurocognitive perspective. J Sleep Res. 1997;6(3):179-188. doi:10.1046/j.1365-2869.1997.00045.x. PMID: 9358396.DOI 10.1046/j.1365-2869.1997.00045.x (abre em nova aba)
  43. Espie CA, Kyle SD, Williams C, et al. A randomized, placebo-controlled trial of online CBT for chronic insomnia disorder delivered via an automated media-rich web application. Sleep. 2012;35(6):769-781. doi:10.5665/sleep.1872. PMID: 22654196.DOI 10.5665/sleep.1872 (abre em nova aba)
  44. Morin CM, Vallières A, Guay B, et al. Cognitive behavioral therapy, singly and combined with medication, for persistent insomnia: a randomized controlled trial. JAMA. 2009;301(19):2005-2015. doi:10.1001/jama.2009.682. PMID: 19454639.DOI 10.1001/jama.2009.682 (abre em nova aba)
  45. Cappuccio FP, D'Elia L, Strazzullo P, Miller MA. Sleep duration and all-cause mortality: a systematic review and meta-analysis of prospective studies. Sleep. 2010;33(5):585-592. doi:10.1093/sleep/33.5.585. PMID: 20469800.DOI 10.1093/sleep/33.5.585 (abre em nova aba)
  46. Cappuccio FP, Cooper D, D'Elia L, Strazzullo P, Miller MA. Sleep duration predicts cardiovascular outcomes: a systematic review and meta-analysis of prospective studies. Eur Heart J. 2011;32(12):1484-1492. doi:10.1093/eurheartj/ehr007. PMID: 21300732.DOI 10.1093/eurheartj/ehr007 (abre em nova aba)
  47. Yin J, Jin X, Shan Z, et al. Relationship of sleep duration with all-cause mortality and cardiovascular events: a systematic review and dose-response meta-analysis of prospective cohort studies. J Am Heart Assoc. 2017;6(9):e005947. doi:10.1161/JAHA.117.005947. PMID: 28889101.DOI 10.1161/JAHA.117.005947 (abre em nova aba)
  48. Shan Z, Ma H, Xie M, et al. Sleep duration and risk of type 2 diabetes: a meta-analysis of prospective studies. Diabetes Care. 2015;38(3):529-537. doi:10.2337/dc14-2073. PMID: 25715415.DOI 10.2337/dc14-2073 (abre em nova aba)
  49. Buxton OM, Cain SW, O'Connor SP, et al. Adverse metabolic consequences in humans of prolonged sleep restriction combined with circadian disruption. Sci Transl Med. 2012;4(129):129ra43. doi:10.1126/scitranslmed.3003200. PMID: 22496545.DOI 10.1126/scitranslmed.3003200 (abre em nova aba)
  50. Buxton OM, Pavlova M, Reid EW, et al. Sleep restriction for 1 week reduces insulin sensitivity in healthy men. Diabetes. 2010;59(9):2126-2133. doi:10.2337/db09-0699. PMID: 20585000.DOI 10.2337/db09-0699 (abre em nova aba)
  51. Knutson KL, Spiegel K, Penev P, Van Cauter E. The metabolic consequences of sleep deprivation. Sleep Med Rev. 2007;11(3):163-178. doi:10.1016/j.smrv.2007.01.002. PMID: 17442599.DOI 10.1016/j.smrv.2007.01.002 (abre em nova aba)
  52. Lyssenko V, Nagorny CLF, Erdos MR, et al. Common variant in MTNR1B associated with increased risk of type 2 diabetes and impaired early insulin secretion. Nat Genet. 2009;41(1):82-88. doi:10.1038/ng.288. PMID: 19060908.DOI 10.1038/ng.288 (abre em nova aba)
  53. Tuomi T, Nagorny CLF, Singh P, et al. Increased melatonin signaling is a risk factor for type 2 diabetes. Cell Metab. 2016;23(6):1067-1077. doi:10.1016/j.cmet.2016.04.009. PMID: 27185156.DOI 10.1016/j.cmet.2016.04.009 (abre em nova aba)
  54. Nedeltcheva AV, Kilkus JM, Imperial J, Schoeller DA, Penev PD. Insufficient sleep undermines dietary efforts to reduce adiposity. Ann Intern Med. 2010;153(7):435-441. doi:10.7326/0003-4819-153-7-201010050-00006. PMID: 20921542.DOI 10.7326/0003-4819-153-7-201010050-00006 (abre em nova aba)
  55. Spiegel K, Tasali E, Penev P, Van Cauter E. Brief communication: sleep curtailment in healthy young men is associated with decreased leptin levels, elevated ghrelin levels, and increased hunger and appetite. Ann Intern Med. 2004;141(11):846-850. doi:10.7326/0003-4819-141-11-200412070-00008. PMID: 15583226.DOI 10.7326/0003-4819-141-11-200412070-00008 (abre em nova aba)
  56. Taheri S, Lin L, Austin D, Young T, Mignot E. Short sleep duration is associated with reduced leptin, elevated ghrelin, and increased body mass index. PLoS Med. 2004;1(3):e62. doi:10.1371/journal.pmed.0010062. PMID: 15602591.DOI 10.1371/journal.pmed.0010062 (abre em nova aba)
  57. Leproult R, Van Cauter E. Effect of 1 week of sleep restriction on testosterone levels in young healthy men. JAMA. 2011;305(21):2173-2174. doi:10.1001/jama.2011.710. PMID: 21632481.DOI 10.1001/jama.2011.710 (abre em nova aba)
  58. Res PT, Groen B, Pennings B, et al. Protein ingestion before sleep improves postexercise overnight recovery. Med Sci Sports Exerc. 2012;44(8):1560-1569. doi:10.1249/MSS.0b013e31824cc363. PMID: 22330017.DOI 10.1249/MSS.0b013e31824cc363 (abre em nova aba)
  59. Trommelen J, van Loon LJC. Pre-sleep protein ingestion to improve the skeletal muscle adaptive response to exercise training. Nutrients. 2016;8(12):763. doi:10.3390/nu8120763. PMID: 27916799.DOI 10.3390/nu8120763 (abre em nova aba)
  60. Parr EB, Camera DM, Areta JL, et al. Alcohol ingestion impairs maximal post-exercise rates of myofibrillar protein synthesis following a single bout of concurrent training. PLoS One. 2014;9(2):e88384. doi:10.1371/journal.pone.0088384. PMID: 24533082.DOI 10.1371/journal.pone.0088384 (abre em nova aba)
  61. Peppard PE, Young T, Barnet JH, et al. Increased prevalence of sleep-disordered breathing in adults. Am J Epidemiol. 2013;177(9):1006-1014. doi:10.1093/aje/kws342. PMID: 23589584.DOI 10.1093/aje/kws342 (abre em nova aba)
  62. Foster GD, Borradaile KE, Sanders MH, et al. A randomized study on the effect of weight loss on obstructive sleep apnea among obese patients with type 2 diabetes (Sleep AHEAD). Arch Intern Med. 2009;169(17):1619-1626. doi:10.1001/archinternmed.2009.266. PMID: 19786682.DOI 10.1001/archinternmed.2009.266 (abre em nova aba)
  63. Au J, Reece J. The relationship between chronotype and depressive symptoms: a meta-analysis. J Affect Disord. 2017;218:93-104. doi:10.1016/j.jad.2017.04.021. PMID: 28463712.DOI 10.1016/j.jad.2017.04.021 (abre em nova aba)
  64. Knutson KL, von Schantz M. Associations between chronotype, morbidity and mortality in the UK Biobank cohort. Chronobiol Int. 2018;35(8):1045-1053. doi:10.1080/07420528.2018.1454458. PMID: 29642757.DOI 10.1080/07420528.2018.1454458 (abre em nova aba)
  65. Merikanto I, Lahti T, Puolijoki H, et al. Associations of chronotype and sleep with cardiovascular diseases and type 2 diabetes. Chronobiol Int. 2013;30(4):470-477. doi:10.3109/07420528.2012.741171. PMID: 23281717.DOI 10.3109/07420528.2012.741171 (abre em nova aba)
  66. Rétey JV, Adam M, Khatami R, et al. A genetic variation in the adenosine A2A receptor gene (ADORA2A) contributes to individual sensitivity to caffeine effects on sleep. Clin Pharmacol Ther. 2007;81(5):692-698. doi:10.1038/sj.clpt.6100102. PMID: 17329997.DOI 10.1038/sj.clpt.6100102 (abre em nova aba)
  67. Buysse DJ, Reynolds CF 3rd, Monk TH, et al. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989;28(2):193-213. doi:10.1016/0165-1781(89)90047-4. PMID: 2748771.DOI 10.1016/0165-1781(89 (abre em nova aba)
  68. Bastien CH, Vallières A, Morin CM. Validation of the Insomnia Severity Index as an outcome measure for insomnia research. Sleep Med. 2001;2(4):297-307. doi:10.1016/S1389-9457(00)00065-4. PMID: 11438246.DOI 10.1016/S1389-9457(00 (abre em nova aba)
  69. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991;14(6):540-545. doi:10.1093/sleep/14.6.540. PMID: 1798888.DOI 10.1093/sleep/14.6.540 (abre em nova aba)
  70. Chung F, Yegneswaran B, Liao P, et al. STOP questionnaire: a tool to screen patients for obstructive sleep apnea. Anesthesiology. 2008;108(5):812-821. doi:10.1097/ALN.0b013e31816d83e4. PMID: 18431116.DOI 10.1097/ALN.0b013e31816d83e4 (abre em nova aba)
  71. Horne JA, Östberg O. A self-assessment questionnaire to determine morningness-eveningness in human circadian rhythms. Int J Chronobiol. 1976;4(2):97-110. PMID: 1027738.PMID 1027738 (abre em nova aba)
  72. Adan A, Almirall H. Horne & Östberg morningness-eveningness questionnaire: a reduced scale. Pers Individ Dif. 1991;12(3):241-253. doi:10.1016/0191-8869(91)90110-W.DOI 10.1016/0191-8869(91 (abre em nova aba)
  73. Morin CM, Vallières A, Ivers H. Dysfunctional Beliefs and Attitudes about Sleep (DBAS): validation of a brief version (DBAS-16). Sleep. 2007;30(11):1547-1554. doi:10.1093/sleep/30.11.1547. PMID: 18041487.DOI 10.1093/sleep/30.11.1547 (abre em nova aba)
  74. Soldatos CR, Dikeos DG, Paparrigopoulos TJ. Athens Insomnia Scale: validation of an instrument based on ICD-10 criteria. J Psychosom Res. 2000;48(6):555-560. doi:10.1016/S0022-3999(00)00095-7. PMID: 11033374.DOI 10.1016/S0022-3999(00 (abre em nova aba)
  75. Roenneberg T, Wirz-Justice A, Merrow M. (MCTQ) — ver ref. 26.
  76. Carney CE, Buysse DJ, Ancoli-Israel S, et al. The consensus sleep diary: standardizing prospective sleep self-monitoring. Sleep. 2012;35(2):287-302. doi:10.5665/sleep.1642. PMID: 22294820.DOI 10.5665/sleep.1642 (abre em nova aba)
  77. Bertolazi AN, Fagondes SC, Hoff LS, et al. Validation of the Brazilian Portuguese version of the Pittsburgh Sleep Quality Index. Sleep Med. 2011;12(1):70-75. doi:10.1016/j.sleep.2010.04.020. PMID: 21145786.DOI 10.1016/j.sleep.2010.04.020 (abre em nova aba)

Regulação Emocional

193 referências · 42 com link direto

  1. McEwen BS. Protective and damaging effects of stress mediators. N Engl J Med. 1998;338(3):171-9. doi:10.1056/NEJM199801153380307. PMID: 9428819.DOI 10.1056/NEJM199801153380307 (abre em nova aba)
  2. Sapolsky RM. Why stress is bad for your brain. Science. 1996;273(5276):749-50. doi:10.1126/science.273.5276.749. PMID: 8701325.DOI 10.1126/science.273.5276.749 (abre em nova aba)
  3. Selye H. A syndrome produced by diverse nocuous agents. Nature. 1936;138:32.
  4. Selye H. The Stress of Life. New York: McGraw-Hill; 1956.
  5. Chrousos GP. Stress and disorders of the stress system. Nat Rev Endocrinol. 2009.
  6. Ulrich-Lai YM, Herman JP. Neural regulation of endocrine and autonomic stress responses. Nat Rev Neurosci. 2009.
  7. de Kloet ER, Joëls M, Holsboer F. Stress and the brain: from adaptation to disease. Nat Rev Neurosci. 2005.
  8. McEwen BS, Wingfield JC. The concept of allostasis in biology and biomedicine. Horm Behav. 2003.
  9. Sapolsky RM. Why Zebras Don't Get Ulcers. 3rd ed. New York: Holt; 2004.
  10. McEwen BS. Physiology and neurobiology of stress and adaptation: central role of the brain. Physiol Rev. 2007.
  11. McEwen BS, Stellar E. Stress and the individual: mechanisms leading to disease. Arch Intern Med. 1993.
  12. Smith SM, Vale WW. The role of the hypothalamic-pituitary-adrenal axis in neuroendocrine responses to stress. Dialogues Clin Neurosci. 2006.
  13. Herman JP, et al. Regulation of the hypothalamic-pituitary-adrenocortical stress response. Compr Physiol. 2016.
  14. Joëls M, Baram TZ. The neuro-symphony of stress. Nat Rev Neurosci. 2009.
  15. Porges SW. The polyvagal theory: phylogenetic substrates of a social nervous system. Int J Psychophysiol. 2001.
  16. Seeman TE, McEwen BS, Rowe JW, Singer BH. Allostatic load as a marker of cumulative biological risk: MacArthur studies of successful aging. Proc Natl Acad Sci U S A. 2001;98(8):4770-5. doi:10.1073/pnas.081072698. PMID: 11287659.DOI 10.1073/pnas.081072698 (abre em nova aba)
  17. Seeman TE, Singer BH, Rowe JW, Horwitz RI, McEwen BS. Price of adaptation — allostatic load and its health consequences. Arch Intern Med. 1997.
  18. Juster RP, McEwen BS, Lupien SJ. Allostatic load biomarkers of chronic stress and impact on health and cognition. Neurosci Biobehav Rev. 2010.
  19. Karlamangla AS, Singer BH, Seeman TE. Reduction in allostatic load in older adults and mortality. Psychosom Med. 2006.
  20. McEwen BS. Allostasis and allostatic load: implications for neuropsychopharmacology. Neuropsychopharmacology. 2000.
  21. Arnsten AFT. Stress signalling pathways that impair prefrontal cortex structure and function. Nat Rev Neurosci. 2009.
  22. McEwen BS, Gianaros PJ. Stress- and allostasis-induced brain plasticity. Annu Rev Med. 2011.
  23. Lupien SJ, McEwen BS, Gunnar MR, Heim C. Effects of stress throughout the lifespan on the brain, behaviour and cognition. Nat Rev Neurosci. 2009.
  24. Liston C, McEwen BS, Casey BJ. Psychosocial stress reversibly disrupts prefrontal processing and attentional control. Proc Natl Acad Sci U S A. 2009.
  25. Roozendaal B, McEwen BS, Chattarji S. Stress, memory and the amygdala. Nat Rev Neurosci. 2009.
  26. Radley JJ, et al. Repeated stress induces dendritic spine loss in the rat medial prefrontal cortex. Cereb Cortex. 2006.
  27. Sheline YI. Depression and the hippocampus: pathophysiological mechanisms. Biol Psychiatry. 2003.
  28. Menon V. Large-scale brain networks and psychopathology: a unifying triple network model. Trends Cogn Sci. 2011.
  29. Seeley WW, et al. Dissociable intrinsic connectivity networks for salience processing and executive control. J Neurosci. 2007.
  30. Raichle ME, et al. A default mode of brain function. Proc Natl Acad Sci U S A. 2001.
  31. Sheline YI, et al. The default mode network and self-referential processes in depression. Proc Natl Acad Sci U S A. 2009.
  32. Kaiser RH, et al. Large-scale network dysfunction in major depressive disorder: meta-analysis of resting-state functional connectivity. JAMA Psychiatry. 2015.
  33. Hamilton JP, et al. Default-mode and task-positive network activity in major depressive disorder. Biol Psychiatry. 2011.
  34. Menon V, Uddin LQ. Saliency, switching, attention and control: a network model of insula function. Brain Struct Funct. 2010.
  35. Nolen-Hoeksema S. Responses to depression and their effects on the duration of depressive episodes. J Abnorm Psychol. 1991;100(4):569-82. doi:10.1037/0021-843X.100.4.569. PMID: 1757671.DOI 10.1037/0021-843X.100.4.569 (abre em nova aba)
  36. Nolen-Hoeksema S, Wisco BE, Lyubomirsky S. Rethinking rumination. Perspect Psychol Sci. 2008;3(5):400-24. doi:10.1111/j.1745-6924.2008.00088.x. PMID: 26158958.DOI 10.1111/j.1745-6924.2008.00088.x (abre em nova aba)
  37. Watkins ER. Constructive and unconstructive repetitive thought. Psychol Bull. 2008.
  38. Treynor W, Gonzalez R, Nolen-Hoeksema S. Rumination reconsidered: a psychometric analysis. Cognit Ther Res. 2003.
  39. Bratman GN, et al. Nature experience reduces rumination and subgenual prefrontal cortex activation. Proc Natl Acad Sci U S A. 2015.
  40. Maslach C, Schaufeli WB, Leiter MP. Job burnout. Annu Rev Psychol. 2001;52:397-422. doi:10.1146/annurev.psych.52.1.397. PMID: 11148311.DOI 10.1146/annurev.psych.52.1.397 (abre em nova aba)
  41. Maslach C, Jackson SE. The measurement of experienced burnout. J Occup Behav. 1981.
  42. West CP, Dyrbye LN, Shanafelt TD. Physician burnout: contributors, consequences and solutions. J Intern Med. 2018.
  43. West CP, et al. Interventions to prevent and reduce physician burnout: systematic review and meta-analysis. Lancet. 2016.
  44. Panagioti M, et al. Controlled interventions to reduce burnout in physicians: systematic review and meta-analysis. JAMA Intern Med. 2017.
  45. Bianchi R, Schonfeld IS, Laurent E. Burnout-depression overlap: a review. Clin Psychol Rev. 2015.
  46. World Health Organization. Burn-out an "occupational phenomenon": International Classification of Diseases (ICD-11, QD85). 2019.
  47. Binder EB, Bradley RG, Liu W, et al. Association of FKBP5 polymorphisms and childhood abuse with risk of posttraumatic stress disorder symptoms in adults. JAMA. 2008;299(11):1291-305. doi:10.1001/jama.299.11.1291. PMID: 18349090.DOI 10.1001/jama.299.11.1291 (abre em nova aba)
  48. Klengel T, Mehta D, Anacker C, et al. Allele-specific FKBP5 DNA demethylation mediates gene-childhood trauma interactions. Nat Neurosci. 2013;16(1):33-41. doi:10.1038/nn.3275. PMID: 23201972.DOI 10.1038/nn.3275 (abre em nova aba)
  49. Caspi A, Sugden K, Moffitt TE, et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science. 2003;301(5631):386-9. doi:10.1126/science.1083968. PMID: 12869766.DOI 10.1126/science.1083968 (abre em nova aba)
  50. Caspi A, McClay J, Moffitt TE, et al. Role of genotype in the cycle of violence in maltreated children. Science. 2002;297(5582):851-4. doi:10.1126/science.1072290. PMID: 12161658.DOI 10.1126/science.1072290 (abre em nova aba)
  51. Zannas AS, Wiechmann T, Gassen NC, Binder EB. Gene-stress-epigenetic regulation of FKBP5: clinical and translational implications. Neuropsychopharmacology. 2016.
  52. Heim C, Binder EB. Current research trends in early life stress and depression: gene-environment interactions and epigenetics. Exp Neurol. 2012.
  53. Risch N, et al. Interaction between the serotonin transporter gene (5-HTTLPR), stressful life events, and risk of depression: meta-analysis. JAMA. 2009.
  54. Duncan LE, Keller MC. A critical review of the first 10 years of candidate gene-by-environment interaction research in psychiatry. Am J Psychiatry. 2011.
  55. Tyrka AR, et al. Childhood adversity and epigenetic regulation of glucocorticoid signaling genes (NR3C1, FKBP5). Dev Psychopathol. 2015.
  56. Hariri AR, et al. Serotonin transporter genetic variation and the response of the human amygdala. Science. 2002.
  57. Goyal M, Singh S, Sibinga EMS, et al. Meditation programs for psychological stress and well-being: a systematic review and meta-analysis. JAMA Intern Med. 2014;174(3):357-68. doi:10.1001/jamainternmed.2013.13018. PMID: 24395196.DOI 10.1001/jamainternmed.2013.13018 (abre em nova aba)
  58. Khoury B, Lecomte T, Fortin G, et al. Mindfulness-based therapy: a comprehensive meta-analysis. Clin Psychol Rev. 2013;33(6):763-71. doi:10.1016/j.cpr.2013.05.005. PMID: 23796855.DOI 10.1016/j.cpr.2013.05.005 (abre em nova aba)
  59. Hölzel BK, Carmody J, Vangel M, et al. Mindfulness practice leads to increases in regional brain gray matter density. Psychiatry Res. 2011;191(1):36-43. doi:10.1016/j.pscychresns.2010.08.006. PMID: 21071182.DOI 10.1016/j.pscychresns.2010.08.006 (abre em nova aba)
  60. Davidson RJ, Kabat-Zinn J, Schumacher J, et al. Alterations in brain and immune function produced by mindfulness meditation. Psychosom Med. 2003;65(4):564-70. doi:10.1097/01.psy.0000077505.67574.e3. PMID: 12883106.DOI 10.1097/01.psy.0000077505.67574.e3 (abre em nova aba)
  61. Tang YY, Hölzel BK, Posner MI. The neuroscience of mindfulness meditation. Nat Rev Neurosci. 2015.
  62. Kabat-Zinn J, et al. Effectiveness of a meditation-based stress reduction program in the treatment of anxiety disorders. Am J Psychiatry. 1992.
  63. Kuyken W, et al. Efficacy of MBCT in prevention of depressive relapse: individual patient data meta-analysis. JAMA Psychiatry. 2016.
  64. Goldberg SB, et al. Mindfulness-based interventions for psychiatric disorders: systematic review and meta-analysis. Clin Psychol Rev. 2018.
  65. Kabat-Zinn J. Full Catastrophe Living. New York: Delacorte; 1990.
  66. Creswell JD. Mindfulness interventions. Annu Rev Psychol. 2017.
  67. Grossman P, Niemann L, Schmidt S, Walach H. Mindfulness-based stress reduction and health benefits: a meta-analysis. J Psychosom Res. 2004.
  68. Sedlmeier P, et al. The psychological effects of meditation: a meta-analysis. Psychol Bull. 2012.
  69. Brewer JA, et al. Meditation experience is associated with differences in default mode network activity and connectivity. Proc Natl Acad Sci U S A. 2011.
  70. Hofmann SG, Sawyer AT, Witt AA, Oh D. The effect of mindfulness-based therapy on anxiety and depression: a meta-analytic review. J Consult Clin Psychol. 2010.
  71. Goessl VC, Curtiss JE, Hofmann SG. The effect of heart rate variability biofeedback training on stress and anxiety: a meta-analysis. Psychol Med. 2017;47(15):2578-86. doi:10.1017/S0033291717001003. PMID: 28478782.DOI 10.1017/S0033291717001003 (abre em nova aba)
  72. Lehrer PM, Gevirtz R. Heart rate variability biofeedback: how and why does it work? Front Psychol. 2014;5:756. doi:10.3389/fpsyg.2014.00756. PMID: 25101026.DOI 10.3389/fpsyg.2014.00756 (abre em nova aba)
  73. Russo MA, Santarelli DM, O'Rourke D. The physiological effects of slow breathing in the healthy human. Breathe. 2017.
  74. Zaccaro A, et al. How breath-control can change your life: systematic review on psycho-physiological correlates of slow breathing. Front Hum Neurosci. 2018.
  75. Balban MY, et al. Brief structured respiration practices enhance mood and reduce physiological arousal. Cell Rep Med. 2023.
  76. Thayer JF, Lane RD. Claude Bernard and the heart-brain connection: neurovisceral integration. Neurosci Biobehav Rev. 2009.
  77. Laborde S, Mosley E, Thayer JF. Heart rate variability and cardiac vagal tone in psychophysiological research. Front Psychol. 2017.
  78. Schuch FB, Vancampfort D, Firth J, et al. Physical activity and incident depression: a meta-analysis of prospective cohort studies. Am J Psychiatry. 2018;175(7):631-48. PMID: 29690792.PMID 29690792 (abre em nova aba)
  79. Noetel M, Sanders T, Gallardo-Gómez D, et al. Effect of exercise for depression: systematic review and network meta-analysis of RCTs. BMJ. 2024;384:e075847. PMID: 38355154.PMID 38355154 (abre em nova aba)
  80. Pearce M, Garcia L, Abbas A, et al. Association between physical activity and risk of depression: a systematic review and meta-analysis. JAMA Psychiatry. 2022;79(6):550-9. PMID: 35416941.PMID 35416941 (abre em nova aba)
  81. Gordon BR, McDowell CP, Hallgren M, et al. Association of efficacy of resistance exercise training with depressive symptoms: meta-analysis and meta-regression of RCTs. JAMA Psychiatry. 2018;75(6):566-76. PMID: 29800984.PMID 29800984 (abre em nova aba)
  82. Cooney GM, Dwan K, Greig CA, et al. Exercise for depression. Cochrane Database Syst Rev. 2013;(9):CD004366. PMID: 24026850.PMID 24026850 (abre em nova aba)
  83. Singh B, Olds T, Curtis R, et al. Effectiveness of physical activity interventions for improving depression, anxiety and distress: an overview of systematic reviews. Br J Sports Med. 2023;57(18):1203-9. PMID: 36796860.PMID 36796860 (abre em nova aba)
  84. Harvey SB, Øverland S, Hatch SL, et al. Exercise and the prevention of depression: results of the HUNT cohort study. Am J Psychiatry. 2018;175(1):28-36. PMID: 28969440.PMID 28969440 (abre em nova aba)
  85. Erickson KI, Voss MW, Prakash RS, et al. Exercise training increases size of hippocampus and improves memory. Proc Natl Acad Sci U S A. 2011;108(7):3017-22. PMID: 21282661.PMID 21282661 (abre em nova aba)
  86. Dinoff A, Herrmann N, Swardfager W, Lanctôt KL. The effect of acute exercise on blood concentrations of BDNF in healthy adults: a meta-analysis. Eur J Neurosci. 2017;46(1):1635-46. PMID: 28493624.PMID 28493624 (abre em nova aba)
  87. Wrann CD, White JP, Salogiannnis J, et al. Exercise induces hippocampal BDNF through a PGC-1α/FNDC5 pathway. Cell Metab. 2013;18(5):649-59. PMID: 24120943.PMID 24120943 (abre em nova aba)
  88. Stubbs B, et al. An examination of the anxiolytic effects of exercise for people with anxiety and stress-related disorders: meta-analysis. Psychiatry Res. 2017.
  89. Schuch FB, et al. Exercise as a treatment for depression: a meta-analysis adjusting for publication bias. J Psychiatr Res. 2016.
  90. Baglioni C, et al. Insomnia as a predictor of depression: a meta-analytic evaluation of longitudinal epidemiological studies. J Affect Disord. 2011.
  91. Meerlo P, Sgoifo A, Suchecki D. Restricted and disrupted sleep: effects on autonomic function, neuroendocrine stress systems and stress responsivity. Sleep Med Rev. 2008.
  92. Van Cauter E, et al. Metabolic consequences of sleep and sleep loss. Sleep Med. 2008.
  93. Walker MP. The role of sleep in cognition and emotion. Ann N Y Acad Sci. 2009.
  94. Goldstein AN, Walker MP. The role of sleep in emotional brain function. Annu Rev Clin Psychol. 2014.
  95. Holt-Lunstad J, Smith TB, Layton JB. Social relationships and mortality risk: a meta-analytic review. PLoS Med. 2010;7(7):e1000316. doi:10.1371/journal.pmed.1000316. PMID: 20668659.DOI 10.1371/journal.pmed.1000316 (abre em nova aba)
  96. Holt-Lunstad J, Smith TB, Baker M, et al. Loneliness and social isolation as risk factors for mortality: a meta-analytic review. Perspect Psychol Sci. 2015;10(2):227-37. doi:10.1177/1745691614568352. PMID: 25910392.DOI 10.1177/1745691614568352 (abre em nova aba)
  97. Office of the U.S. Surgeon General. Our Epidemic of Loneliness and Isolation: Advisory on the Healing Effects of Social Connection. 2023.
  98. Cacioppo JT, Hawkley LC. Social isolation and health, with an emphasis on underlying mechanisms. Perspect Biol Med. 2003.
  99. Uchino BN. Social support and health: a review of physiological processes. J Behav Med. 2006.
  100. Waldinger RJ, Schulz MS. The Harvard Study of Adult Development. (livro "The Good Life", 2023).
  101. Berkman LF, Syme SL. Social networks, host resistance, and mortality: a nine-year follow-up of Alameda County residents. Am J Epidemiol. 1979.
  102. House JS, Landis KR, Umberson D. Social relationships and health. Science. 1988.
  103. Rosengren A, Hawken S, Ounpuu S, et al. Association of psychosocial risk factors with risk of acute myocardial infarction in 11119 cases and 13648 controls from 52 countries (INTERHEART): case-control study. Lancet. 2004;364(9438):953-62. doi:10.1016/S0140-6736(04)17019-0. PMID: 15364186.DOI 10.1016/S0140-6736(04 (abre em nova aba)
  104. Kivimäki M, Nyberg ST, Batty GD, et al. Job strain as a risk factor for coronary heart disease: a collaborative meta-analysis of individual participant data. Lancet. 2012;380(9852):1491-7. doi:10.1016/S0140-6736(12)60994-5. PMID: 22981903.DOI 10.1016/S0140-6736(12 (abre em nova aba)
  105. Steptoe A, Kivimäki M. Stress and cardiovascular disease. Nat Rev Cardiol. 2012;9(6):360-70. doi:10.1038/nrcardio.2012.45. PMID: 22473079.DOI 10.1038/nrcardio.2012.45 (abre em nova aba)
  106. Kivimäki M, Steptoe A. Effects of stress on the development and progression of cardiovascular disease. Nat Rev Cardiol. 2018.
  107. Dimsdale JE. Psychological stress and cardiovascular disease. J Am Coll Cardiol. 2008.
  108. Tawakol A, et al. Relation between resting amygdalar activity and cardiovascular events: a longitudinal and cohort study. Lancet. 2017.
  109. Segerstrom SC, Miller GE. Psychological stress and the human immune system: meta-analytic study of 30 years of inquiry. Psychol Bull. 2004.
  110. Cohen S, et al. Chronic stress, glucocorticoid receptor resistance, inflammation, and disease risk. Proc Natl Acad Sci U S A. 2012.
  111. Slavich GM, Irwin MR. From stress to inflammation and major depressive disorder: a social signal transduction theory of depression. Psychol Bull. 2014.
  112. Miller GE, Cohen S, Ritchey AK. Chronic psychological stress and the regulation of pro-inflammatory cytokines: a glucocorticoid-resistance model. Health Psychol. 2002.
  113. Marsland AL, et al. The effects of acute psychological stress on circulating inflammatory factors: meta-analysis. Brain Behav Immun. 2017.
  114. Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med. 2009.
  115. Dhabhar FS. Effects of stress on immune function: the good, the bad, and the beautiful. Immunol Res. 2014.
  116. Epel ES, Blackburn EH, Lin J, et al. Accelerated telomere shortening in response to life stress. Proc Natl Acad Sci U S A. 2004;101(49):17312-5. doi:10.1073/pnas.0407162101. PMID: 15574496.DOI 10.1073/pnas.0407162101 (abre em nova aba)
  117. Ornish D, Lin J, Chan JM, et al. Effect of comprehensive lifestyle changes on telomerase activity and telomere length in low-risk prostate cancer: 5-year follow-up. Lancet Oncol. 2013;14(11):1112-20. PMID: 24051140.PMID 24051140 (abre em nova aba)
  118. Mathur MB, et al. Perceived stress and telomere length: systematic review, meta-analysis. Brain Behav Immun. 2016.
  119. Lin J, Epel E, Blackburn E. Telomeres and lifestyle factors: roles in cellular aging. Mutat Res. 2012.
  120. Tomiyama AJ, Mann T, Vinas D, et al. Low calorie dieting increases cortisol. Psychosom Med. 2010;72(4):357-64. doi:10.1097/PSY.0b013e3181d9523c. PMID: 20368473.DOI 10.1097/PSY.0b013e3181d9523c (abre em nova aba)
  121. Björntorp P. Do stress reactions cause abdominal obesity and comorbidities? Obes Rev. 2001.
  122. Epel ES, et al. Stress and body shape: stress-induced cortisol secretion is consistently greater among women with central fat. Psychosom Med. 2000.
  123. Adam TC, Epel ES. Stress, eating and the reward system. Physiol Behav. 2007.
  124. Dallman MF, et al. Chronic stress and obesity: a new view of "comfort food". Proc Natl Acad Sci U S A. 2003.
  125. Cuijpers P, van Straten A, Andersson G, van Oppen P. Psychotherapy for depression in adults: a meta-analysis of comparative outcome studies. J Consult Clin Psychol. 2008;76(6):909-22. doi:10.1037/a0013075. PMID: 19045960.DOI 10.1037/a0013075 (abre em nova aba)
  126. Manber R, Edinger JD, Gress JL, et al. Cognitive behavioral therapy for insomnia enhances depression outcome in patients with comorbid MDD and insomnia. Sleep. 2008;31(4):489-95. doi:10.1093/sleep/31.4.489. PMID: 18457236.DOI 10.1093/sleep/31.4.489 (abre em nova aba)
  127. Hofmann SG, et al. The efficacy of cognitive behavioral therapy: a review of meta-analyses. Cognit Ther Res. 2012.
  128. Cuijpers P, et al. The effects of psychotherapies for major depression in adults on remission, recovery and improvement: meta-analysis. J Affect Disord. 2014.
  129. A-Tjak JGL, et al. A meta-analysis of the efficacy of acceptance and commitment therapy. Psychother Psychosom. 2015.
  130. Lopresti AL, Smith SJ, Malvi H, Kodgule R. An investigation into the stress-relieving and pharmacological actions of an ashwagandha (Withania somnifera) extract: a randomized, double-blind, placebo-controlled study. Medicine (Baltimore). 2019;98(37):e17186. doi:10.1097/MD.0000000000017186. PMID: 31517876.DOI 10.1097/MD.0000000000017186 (abre em nova aba)
  131. Salve J, et al. Adaptogenic and anxiolytic effects of ashwagandha root extract in healthy adults: double-blind RCT. Cureus. 2019.
  132. Pratte MA, et al. An alternative treatment for anxiety: systematic review of human trials of ashwagandha. J Altern Complement Med. 2014.
  133. Boyle NB, Lawton C, Dye L. The effects of magnesium supplementation on subjective anxiety and stress: systematic review. Nutrients. 2017.
  134. Anghelescu IG, et al. Stress management and the role of Rhodiola rosea: a review. Int J Psychiatry Clin Pract. 2018.
  135. Jacka FN, O'Neil A, Opie R, et al. A randomised controlled trial of dietary improvement for adults with major depression (the SMILES trial). BMC Med. 2017;15(1):23. doi:10.1186/s12916-017-0791-y. PMID: 28137247.DOI 10.1186/s12916-017-0791-y (abre em nova aba)
  136. Estruch R, et al. Primary prevention of cardiovascular disease with a Mediterranean diet (PREDIMED). N Engl J Med. 2013 (retratado e republicado 2018).
  137. Firth J, et al. The effects of dietary improvement on symptoms of depression and anxiety: meta-analysis of RCTs. Psychosom Med. 2019.
  138. Marx W, et al. Nutritional psychiatry: the present state of the evidence. Proc Nutr Soc. 2017.
  139. Lassale C, et al. Healthy dietary indices and risk of depressive outcomes: systematic review and meta-analysis. Mol Psychiatry. 2019.
  140. Mattson MP. Hormesis defined. Ageing Res Rev. 2008.
  141. Laukkanen T, et al. Sauna bathing and risk of cardiovascular and all-cause mortality events. (coorte KIHD). 2018.
  142. de Cabo R, Mattson MP. Effects of intermittent fasting on health, aging, and disease. N Engl J Med. 2019.
  143. Patrick RP, Johnson TL. Sauna use as a lifestyle practice to extend healthspan. Exp Gerontol. 2021.
  144. Buijze GA, et al. The effect of cold showering on health and work: randomized controlled trial. PLoS One. 2016.
  145. Yehuda R, et al. Post-traumatic stress disorder. Nat Rev Dis Primers. 2015.
  146. Pitman RK, et al. Biological studies of post-traumatic stress disorder. Nat Rev Neurosci. 2012.
  147. Liberzon I, Abelson JL. Context processing and the neurobiology of PTSD. Neuron. 2016.
  148. van der Kolk BA. The Body Keeps the Score. New York: Viking; 2014.
  149. Milad MR, Quirk GJ. Fear extinction as a model for translational neuroscience. Annu Rev Psychol. 2012.
  150. Shalev A, Liberzon I, Marmar C. Post-traumatic stress disorder. N Engl J Med. 2017.
  151. Stalder T, et al. Assessment of the cortisol awakening response: expert consensus guidelines. Psychoneuroendocrinology. 2016.
  152. Clow A, et al. The cortisol awakening response: methodological issues and significance. Stress. 2004.
  153. Adam EK, Kumari M. Assessing salivary cortisol in large-scale, epidemiological research. Psychoneuroendocrinology. 2009.
  154. Fries E, Dettenborn L, Kirschbaum C. The cortisol awakening response (CAR): facts and future directions. Int J Psychophysiol. 2009.
  155. Adam EK, et al. Diurnal cortisol slopes and mental and physical health outcomes: systematic review and meta-analysis. Psychoneuroendocrinology. 2017.
  156. Ornish D, et al. Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial. Lancet. 1990.
  157. Ornish D, et al. Intensive lifestyle changes for reversal of coronary heart disease. JAMA. 1998.
  158. Knowler WC, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin (DPP). N Engl J Med. 2002.
  159. Lean MEJ, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT). Lancet. 2018.
  160. Lianov L, Johnson M. Physician competencies for prescribing lifestyle medicine. JAMA. 2010.
  161. American College of Lifestyle Medicine. Lifestyle Medicine Standards. (documento de posição).
  162. Kahneman D, Tversky A. Prospect theory: an analysis of decision under risk. Econometrica. 1979.
  163. Rothman AJ, Salovey P. Shaping perceptions to motivate healthy behavior: the role of message framing. Psychol Bull. 1997.
  164. Gallagher KM, Updegraff JA. Health message framing effects on attitudes, intentions, and behavior: meta-analytic review. Ann Behav Med. 2012.
  165. Gallagher KM, Updegraff JA, Rothman AJ, Sims L. Perceived susceptibility to breast cancer moderates the effect of gain- and loss-framed messages. Health Psychol. 2011.
  166. Gollwitzer PM, Sheeran P. Implementation intentions and goal achievement: meta-analysis of effects and processes. Adv Exp Soc Psychol. 2006.
  167. Boyce WT, Ellis BJ. Biological sensitivity to context: an evolutionary-developmental theory of the origins and functions of stress reactivity. Dev Psychopathol. 2005.
  168. Belsky J, Pluess M. Beyond diathesis stress: differential susceptibility to environmental influences. Psychol Bull. 2009.
  169. Aron EN, Aron A. Sensory-processing sensitivity and its relation to introversion and emotionality. J Pers Soc Psychol. 1997.
  170. Pluess M. Individual differences in environmental sensitivity. Child Dev Perspect. 2015.
  171. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606-13. doi:10.1046/j.1525-1497.2001.016009606.x. PMID: 11556941.DOI 10.1046/j.1525-1497.2001.016009606.x (abre em nova aba)
  172. Spitzer RL, Kroenke K, Williams JB, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166(10):1092-7. doi:10.1001/archinte.166.10.1092. PMID: 16717171.DOI 10.1001/archinte.166.10.1092 (abre em nova aba)
  173. Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. J Health Soc Behav. 1983;24(4):385-96. PMID: 6668417.PMID 6668417 (abre em nova aba)
  174. Buysse DJ, Reynolds CF 3rd, Monk TH, et al. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989;28(2):193-213. doi:10.1016/0165-1781(89)90047-4. PMID: 2748771.DOI 10.1016/0165-1781(89 (abre em nova aba)
  175. Bastien CH, Vallières A, Morin CM. Validation of the Insomnia Severity Index as an outcome measure for insomnia research. Sleep Med. 2001.
  176. West CP, et al. Concurrent validity of single-item measures of emotional exhaustion and depersonalization in burnout assessment. J Gen Intern Med. 2009.
  177. Nasreddine ZS, et al. The Montreal Cognitive Assessment (MoCA): a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005.
  178. Smarr KL, Keefer AL. Measures of depression and depression screening: BDI-II, CES-D, GDS, PHQ-9. Arthritis Care Res. 2011.
  179. Kirschbaum C, Pirke KM, Hellhammer DH. The 'Trier Social Stress Test' — a tool for investigating psychobiological stress responses in a laboratory setting. Neuropsychobiology. 1993.
  180. Chida Y, Steptoe A. Greater cardiovascular responses to laboratory mental stress are associated with poor subsequent cardiovascular risk status: meta-analysis. Hypertension. 2010.
  181. Karasek RA. Job demands, job decision latitude, and mental strain: implications for job redesign. Adm Sci Q. 1979.
  182. Southwick SM, Charney DS. The science of resilience: implications for the prevention and treatment of depression. Science. 2012.
  183. Russo SJ, Murrough JW, Han MH, Charney DS, Nestler EJ. Neurobiology of resilience. Nat Neurosci. 2012.
  184. McGonigal K. The Upside of Stress. New York: Avery; 2015.
  185. Crum AJ, Salovey P, Achor S. Rethinking stress: the role of mindsets in determining the stress response. J Pers Soc Psychol. 2013.
  186. Jamieson JP, et al. Mind over matter: reappraising arousal improves cardiovascular and cognitive responses to stress. J Exp Psychol Gen. 2012.
  187. Dickerson SS, Kemeny ME. Acute stressors and cortisol responses: a theoretical integration and synthesis of laboratory research. Psychol Bull. 2004.
  188. Epel ES, et al. More than a feeling: a unified view of stress measurement for population science. Front Neuroendocrinol. 2018.
  189. Kandola A, et al. Physical activity and depression: towards understanding the antidepressant mechanisms of physical activity. Neurosci Biobehav Rev. 2019.
  190. Kvam S, et al. Exercise as a treatment for depression: a meta-analysis. J Affect Disord. 2016.
  191. Stubbs B, et al. Physical activity and depression: large cross-sectional and prospective associations. (estudos de coorte). 2018.
  192. Mammen G, Faulkner G. Physical activity and the prevention of depression: systematic review of prospective studies. Am J Prev Med. 2013.
  193. World Health Organization. WHO guidelines on physical activity and sedentary behaviour. 2020.

Comportamentos

210 referências · 11 com link direto

  1. Volkow ND, Koob GF, McLellan AT. Neurobiologic advances from the brain disease model of addiction. N Engl J Med. 2016;374(4):363-371. doi:10.1056/NEJMra1511480. PMID: 26816013.DOI 10.1056/NEJMra1511480 (abre em nova aba)
  2. Leshner AI. Addiction is a brain disease, and it matters. Science. 1997;278(5335):45-47.
  3. American Society of Addiction Medicine (ASAM). Definition of addiction. 2011/2019.
  4. McLellan AT, Lewis DC, O'Brien CP, Kleber HD. Drug dependence, a chronic medical illness. JAMA. 2000;284(13):1689-1695.
  5. Heyman GM. Addiction: a disorder of choice. Harvard University Press; 2009.
  6. Heyman GM. Quitting drugs: quantitative and qualitative features. Annu Rev Clin Psychol. 2013;9:29-59.
  7. Lewis M. Addiction and the brain: development, not disease. Neuroethics. 2017;10(1):7-18.
  8. Lewis M. The biology of desire: why addiction is not a disease. PublicAffairs; 2015.
  9. Hart CL. High price. Harper; 2013.
  10. Szalavitz M. Unbroken brain: a revolutionary new way of understanding addiction. St. Martin's Press; 2016.
  11. Alexander BK, Coambs RB, Hadaway PF. The effect of housing and gender on morphine self-administration in rats (Rat Park). Psychopharmacology. 1978;58(2):175-179.
  12. Robins LN, Helzer JE, Hesselbrock M, Wish E. Vietnam veterans three years after Vietnam. Am J Addict. 2010;19(3):203-211.
  13. Olds J, Milner P. Positive reinforcement produced by electrical stimulation of septal area and other regions of rat brain. J Comp Physiol Psychol. 1954;47(6):419-427.
  14. Wise RA. Neuroleptics and operant behavior: the anhedonia hypothesis. Behav Brain Sci. 1982;5(1):39-87.
  15. Wise RA. Brain reward circuitry: insights from unsensed incentives. Neuron. 2002;36(2):229-240.
  16. Di Chiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. PNAS. 1988;85(14):5274-5278.
  17. Schultz W, Dayan P, Montague PR. A neural substrate of prediction and reward. Science. 1997;275(5306):1593-1599.
  18. Schultz W. Predictive reward signal of dopamine neurons. J Neurophysiol. 1998;80(1):1-27.
  19. Salamone JD, Correa M. The mysterious motivational functions of mesolimbic dopamine. Neuron. 2012;76(3):470-485.
  20. Salamone JD, Correa M. The neurobiology of activational aspects of motivation: effort-based decision making and dopamine. Annu Rev Psychol. 2024.
  21. Berridge KC, Robinson TE. What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience? Brain Res Rev. 1998;28(3):309-369.
  22. Mohebi A, Pettibone JR, Hamid AA, et al. Dissociable dopamine dynamics for learning and motivation. Nature. 2019;570(7759):65-70.
  23. Berridge KC, Kringelbach ML. Pleasure systems in the brain. Neuron. 2015;86(3):646-664.
  24. Wise RA, Rompre PP. Brain dopamine and reward. Annu Rev Psychol. 1989;40:191-225.
  25. Berridge KC, Robinson TE. Liking, wanting, and the incentive-sensitization theory of addiction. Am Psychol. 2016;71(8):670-679. PMID: 27977239.PMID 27977239 (abre em nova aba)
  26. Robinson TE, Berridge KC. The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Rev. 1993;18(3):247-291.
  27. Robinson TE, Berridge KC. The incentive-sensitization theory of addiction 30 years on. Annu Rev Psychol. 2024/2025.
  28. Robinson TE, Berridge KC. The psychology and neurobiology of addiction: an incentive-sensitization view. Addiction. 2000;95(8s2):91-117.
  29. Tindell AJ, Berridge KC, Zhang J, et al. Ventral pallidal neurons code incentive motivation. Eur J Neurosci. 2005;22(10):2617-2634.
  30. Wyvell CL, Berridge KC. Incentive sensitization by previous amphetamine exposure. J Neurosci. 2001;21(19):7831-7840.
  31. Robinson TE, Berridge KC. The incentive sensitization theory of addiction: some current issues. Philos Trans R Soc B. 2008;363(1507):3137-3146.
  32. Flagel SB, Clark JJ, Robinson TE, et al. A selective role for dopamine in stimulus-reward learning. Nature. 2011;469(7328):53-57.
  33. Anderson BA, Yantis S. Persistence of value-driven attentional capture. J Exp Psychol Hum Percept Perform. 2013.
  34. Robinson MJF, Berridge KC. Instant transformation of learned repulsion into motivational "wanting". Curr Biol. 2013;23(4):282-289.
  35. Koob GF, Volkow ND. Neurocircuitry of addiction. Neuropsychopharmacology. 2010;35(1):217-238. doi:10.1038/npp.2009.110.DOI 10.1038/npp.2009.110 (abre em nova aba)
  36. Koob GF, Le Moal M. Drug abuse: hedonic homeostatic dysregulation. Science. 1997;278(5335):52-58.
  37. Koob GF, Le Moal M. Addiction and the brain antireward system. Annu Rev Psychol. 2008;59:29-53.
  38. Koob GF, Volkow ND. Neurobiology of addiction: a neurocircuitry analysis. Lancet Psychiatry. 2016;3(8):760-773.
  39. Solomon RL, Corbit JD. An opponent-process theory of motivation. Psychol Rev. 1974;81(2):119-145.
  40. Sinha R. Chronic stress, drug use, and vulnerability to addiction. Ann N Y Acad Sci. 2008;1141:105-130.
  41. Heilig M, Koob GF. A key role for corticotropin-releasing factor in alcohol dependence. Trends Neurosci. 2007;30(8):399-406.
  42. Volkow ND, Wang GJ, Fowler JS, et al. Addiction: decreased reward sensitivity and increased expectation sensitivity. BioEssays. 2010;32(9):748-755.
  43. George O, Koob GF. Individual differences in the neuropsychopathology of addiction. Dialogues Clin Neurosci. 2017;19(3):217-228.
  44. Koob GF. Anhedonia, hyperkatifeia, and negative reinforcement in addiction. Curr Top Behav Neurosci. 2022.
  45. Everitt BJ, Robbins TW. Neural systems of reinforcement for drug addiction: from actions to habits to compulsion. Nat Neurosci. 2005;8(11):1481-1489. PMID: 16251991.PMID 16251991 (abre em nova aba)
  46. Everitt BJ, Robbins TW. Drug addiction: updating actions to habits to compulsions ten years on. Annu Rev Psychol. 2016;67:23-50.
  47. Vanderschuren LJ, Everitt BJ. Drug seeking becomes compulsive after prolonged cocaine self-administration. Science. 2004;305(5686):1017-1019.
  48. Belin D, Everitt BJ. Cocaine seeking habits depend upon dopamine-dependent serial connectivity linking ventral with dorsal striatum. Neuron. 2008;57(3):432-441.
  49. Tiffany ST. A cognitive model of drug urges and drug-use behavior. Psychol Rev. 1990;97(2):147-168.
  50. Jentsch JD, Taylor JR. Impulsivity resulting from frontostriatal dysfunction in drug abuse. Psychopharmacology. 1999;146(4):373-390.
  51. Ito R, Dalley JW, Robbins TW, Everitt BJ. Dopamine release in the dorsal striatum during cocaine-seeking under cue control. J Neurosci. 2002;22(14):6247-6253.
  52. Corbit LH, Janak PH. Habitual alcohol seeking: dorsolateral striatal control. Alcohol Clin Exp Res. 2016.
  53. Hogarth L. Addiction is driven by excessive goal-directed drug choice under negative affect: translational critique of habit and compulsion theory. Neuropsychopharmacology. 2020;45(5):720-735.
  54. Goldstein RZ, Volkow ND. Drug addiction and its underlying neurobiological basis: neuroimaging evidence for the involvement of the frontal cortex. Am J Psychiatry. 2002;159(10):1642-1652.
  55. Goldstein RZ, Volkow ND. Dysfunction of the prefrontal cortex in addiction: neuroimaging findings and clinical implications (iRISA). Nat Rev Neurosci. 2011;12(11):652-669.
  56. Bechara A. Decision making, impulse control and loss of willpower to resist drugs: a neurocognitive perspective. Nat Neurosci. 2005;8(11):1458-1463.
  57. Diamond A. Executive functions. Annu Rev Psychol. 2013;64:135-168.
  58. Volkow ND, Fowler JS. Addiction, a disease of compulsion and drive: involvement of the orbitofrontal cortex. Cereb Cortex. 2000;10(3):318-325.
  59. Goldstein RZ, Craig AD, Bechara A, et al. The neurocircuitry of impaired insight in drug addiction. Trends Cogn Sci. 2009;13(9):372-380.
  60. Dalley JW, Everitt BJ, Robbins TW. Impulsivity, compulsivity, and top-down cognitive control. Neuron. 2011;69(4):680-694.
  61. Garavan H, Stout JC. Neurocognitive insights into substance abuse. Trends Cogn Sci. 2005;9(4):195-201.
  62. Heatherton TF, Wagner DD. Cognitive neuroscience of self-regulation failure. Trends Cogn Sci. 2011;15(3):132-139.
  63. Hofmann W, Friese M, Strack F. Impulse and self-control from a dual-systems perspective. Perspect Psychol Sci. 2009;4(2):162-176.
  64. Nestler EJ. Molecular basis of long-term plasticity underlying addiction. Nat Rev Neurosci. 2001;2(2):119-128.
  65. Hyman SE, Malenka RC, Nestler EJ. Neural mechanisms of addiction: the role of reward-related learning and memory. Annu Rev Neurosci. 2006;29:565-598.
  66. Kelz MB, Chen J, Carlezon WA, et al. Expression of the transcription factor ΔFosB controls sensitivity to cocaine. Nature. 1999;401(6750):272-276.
  67. Robison AJ, Nestler EJ. Transcriptional and epigenetic mechanisms of addiction. Nat Rev Neurosci. 2011;12(11):623-637.
  68. Hyman SE. Addiction: a disease of learning and memory. Am J Psychiatry. 2005;162(8):1414-1422.
  69. Lüscher C, Malenka RC. Drug-evoked synaptic plasticity in addiction: from molecular changes to circuit remodeling. Neuron. 2011;69(4):650-663.
  70. Ungless MA, Whistler JL, Malenka RC, Bonci A. Single cocaine exposure in vivo induces long-term potentiation in dopamine neurons. Nature. 2001;411(6837):583-587.
  71. Kauer JA, Malenka RC. Synaptic plasticity and addiction. Nat Rev Neurosci. 2007;8(11):844-858.
  72. Kalivas PW. The glutamate homeostasis hypothesis of addiction. Nat Rev Neurosci. 2009;10(8):561-572.
  73. Volkow ND, Fowler JS, Wang GJ, et al. Decreased dopamine D2 receptor availability is associated with reduced frontal metabolism in cocaine abusers. Synapse. 1993;14(2):169-177.
  74. Volkow ND, Wang GJ, Fowler JS, et al. Decreased striatal dopaminergic responsiveness in detoxified cocaine-dependent subjects. Nature. 1997;386(6627):830-833.
  75. Volkow ND, Wang GJ, Telang F, et al. Cocaine cues and dopamine in dorsal striatum: mechanism of craving in cocaine addiction. J Neurosci. 2006;26(24):6583-6588.
  76. Volkow ND, Morales M. The brain on drugs: from reward to addiction. Cell. 2015;162(4):712-725.
  77. Childress AR, Mozley PD, McElgin W, et al. Limbic activation during cue-induced cocaine craving. Am J Psychiatry. 1999;156(1):11-18.
  78. Garavan H, Pankiewicz J, Bloom A, et al. Cue-induced cocaine craving: neuroanatomical specificity. Am J Psychiatry. 2000;157(11):1789-1798.
  79. Ersche KD, Jones PS, Williams GB, et al. Abnormal brain structure implicated in stimulant drug addiction. Science. 2012;335(6068):601-604.
  80. Volkow ND, Fowler JS, Wang GJ. The addicted human brain: insights from imaging studies. J Clin Invest. 2003;111(10):1444-1451.
  81. Martinez D, Narendran R, Foltin RW, et al. Amphetamine-induced dopamine release: markedly blunted in cocaine dependence and predictive of treatment response. Am J Psychiatry. 2007;164(4):622-629.
  82. Ainslie G. Specious reward: a behavioral theory of impulsiveness and impulse control. Psychol Bull. 1975;82(4):463-496.
  83. Bickel WK, Marsch LA. Toward a behavioral economic understanding of drug dependence: delay discounting processes. Addiction. 2001;96(1):73-86.
  84. MacKillop J, Amlung MT, Few LR, et al. Delay discounting of monetary rewards in addictive behaviors: a meta-analysis. Psychopharmacology. 2011;216(3):305-321.
  85. Redish AD. Addiction as a computational process gone awry. Science. 2004;306(5703):1944-1947.
  86. Redish AD, Jensen S, Johnson A. A unified framework for addiction: vulnerabilities in the decision process. Behav Brain Sci. 2008;31(4):415-437.
  87. Daw ND, Niv Y, Dayan P. Uncertainty-based competition between prefrontal and dorsolateral striatal systems for behavioral control. Nat Neurosci. 2005;8(12):1704-1711.
  88. Bickel WK, Koffarnus MN, Moody L, Wilson AG. The behavioral- and neuro-economic process of temporal discounting. Neuropharmacology. 2014;76:518-527.
  89. Volkow ND, Baler RD. Addiction science: uncovering neurobiological complexity. Neuropharmacology. 2014;76:235-249.
  90. Ersche KD, Turton AJ, Pradhan S, et al. Drug addiction endophenotypes: impulsive versus sensation-seeking personality traits. Biol Psychiatry. 2010;68(8):770-773.
  91. Blum K, Noble EP, Sheridan PJ, et al. Allelic association of human dopamine D2 receptor gene in alcoholism. JAMA. 1990;263(15):2055-2060.
  92. Noble EP. D2 dopamine receptor gene in psychiatric and neurologic disorders and its phenotypes. Am J Med Genet B. 2003;116B(1):103-125.
  93. Pohjalainen T, Rinne JO, Någren K, et al. The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers. Mol Psychiatry. 1998;3(3):256-260.
  94. Munafò MR, Yalcin B, Willis-Owen SA, Flint J. Association of the dopamine D4 receptor (DRD4) gene and approach-related personality traits: meta-analysis. Biol Psychiatry. 2008;63(2):197-206.
  95. Ray LA, Hutchison KE. A polymorphism of the mu-opioid receptor gene (OPRM1) and sensitivity to the effects of alcohol in humans. Alcohol Clin Exp Res. 2004;28(12):1789-1795.
  96. Walters RK, Polimanti R, Johnson EC, et al. Transancestral GWAS of alcohol dependence reveals common genetic underpinnings with psychiatric disorders. Nat Neurosci. 2018;21(12):1656-1669.
  97. Sanchez-Roige S, Palmer AA, Clarke TK. Recent efforts to dissect the genetic basis of alcohol use and abuse. Biol Psychiatry. 2020;87(7):609-618.
  98. Thorgeirsson TE, Geller F, Sulem P, et al. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease (CHRNA5/A3). Nature. 2008;452(7187):638-642.
  99. Edenberg HJ. The genetics of alcohol metabolism: role of ADH and ALDH variants. Alcohol Res Health. 2007;30(1):5-13.
  100. Agrawal A, Lynskey MT. Are there genetic influences on addiction: evidence from family, adoption and twin studies. Addiction. 2008;103(7):1069-1081.
  101. Bierut LJ. Genetic vulnerability and susceptibility to substance dependence. Neuron. 2011;69(4):618-627.
  102. Gelernter J, Polimanti R. Genetics of substance use disorders in the era of big data. Nat Rev Genet. 2021;22(11):712-729.
  103. Comings DE, Blum K. Reward deficiency syndrome: genetic aspects of behavioral disorders. Prog Brain Res. 2000;126:325-341.
  104. Jonas DE, Amick HR, Feltner C, et al. Pharmacotherapy for adults with alcohol use disorders in outpatient settings: systematic review and meta-analysis. JAMA. 2014;311(18):1889-1900. PMID: 24825644.PMID 24825644 (abre em nova aba)
  105. Li J, Wang H, Li M, et al. Effect of alcohol use disorders and alcohol intake on the risk of subsequent depressive symptoms: systematic review and meta-analysis of cohort studies. Addiction. 2020;115(7):1224-1243. PMID: 31837230.PMID 31837230 (abre em nova aba)
  106. Puddephatt JA, Irizar P, Jones A, et al. Associations of common mental disorder with alcohol use in the adult general population: systematic review and meta-analysis. Addiction. 2022;117(6):1543-1572. PMID: 34729837.PMID 34729837 (abre em nova aba)
  107. GBD 2016 Alcohol Collaborators. Alcohol use and burden for 195 countries and territories, 1990–2016. Lancet. 2018;392(10152):1015-1035.
  108. Volpicelli JR, Alterman AI, Hayashida M, O'Brien CP. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry. 1992;49(11):876-880.
  109. Anton RF, O'Malley SS, Ciraulo DA, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study. JAMA. 2006;295(17):2003-2017.
  110. Kranzler HR, Feinn R, Morris P, Hartwell EE. Topiramate vs naltrexone for alcohol use disorder: genotype-stratified RCT. Am J Psychiatry. 2024.
  111. Palpacuer C, Duprez R, Huneau A, et al. Pharmacologically controlled drinking in the treatment of alcohol dependence: network meta-analysis. Addiction. 2018;113(2):220-237.
  112. Maisel NC, Blodgett JC, Wilbourne PL, et al. Meta-analysis of naltrexone and acamprosate for alcohol use disorders. Addiction. 2013;108(2):275-293.
  113. Witkiewitz K, Litten RZ, Leggio L. Advances in the science and treatment of alcohol use disorder. Sci Adv. 2019;5(9):eaax4043.
  114. Rehm J, Gmel GE, Gmel G, et al. The relationship between different dimensions of alcohol use and the burden of disease. Addiction. 2017;112(6):968-1001.
  115. Sordo L, Barrio G, Bravo MJ, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:j1550. PMID: 28446428.PMID 28446428 (abre em nova aba)
  116. Dole VP, Nyswander M. A medical treatment for diacetylmorphine (heroin) addiction. JAMA. 1965;193(8):646-650.
  117. Volkow ND, Frieden TR, Hyde PS, Cha SS. Medication-assisted therapies — tackling the opioid-overdose epidemic. N Engl J Med. 2014;370(22):2063-2066.
  118. Ma J, Bao YP, Wang RJ, et al. Effects of medication-assisted treatment on mortality among opioid use disorder: meta-analysis. Mol Psychiatry. 2019;24(12):1868-1883.
  119. Larochelle MR, Bernson D, Land T, et al. Medication for opioid use disorder after nonfatal opioid overdose and association with mortality. Ann Intern Med. 2018;169(3):137-145.
  120. Wakeman SE, Larochelle MR, Ameli O, et al. Comparative effectiveness of different treatment pathways for opioid use disorder. JAMA Netw Open. 2020;3(2):e1920622.
  121. Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014;(2):CD002207.
  122. Santo T, Clark B, Hickman M, et al. Association of opioid agonist treatment with all-cause mortality and specific causes of death. JAMA Psychiatry. 2021;78(9):979-993.
  123. Degenhardt L, Grebely J, Stone J, et al. Global patterns of opioid use and dependence. Lancet. 2019;394(10208):1560-1579.
  124. Taylor G, McNeill A, Girling A, et al. Change in mental health after smoking cessation: systematic review and meta-analysis. BMJ. 2014;348:g1151. PMID: 24524926.PMID 24524926 (abre em nova aba)
  125. Wootton RE, Richmond RC, Stuijfzand BG, et al. Evidence for causal effects of lifetime smoking on risk for depression and schizophrenia: a Mendelian randomisation study. Psychol Med. 2020;50(14):2435-2443. PMID: 31689377.PMID 31689377 (abre em nova aba)
  126. Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions for smoking cessation: network meta-analysis. Cochrane Database Syst Rev. 2013;(5):CD009329.
  127. Hartmann-Boyce J, Chepkin SC, Ye W, et al. Nicotine replacement therapy versus control for smoking cessation. Cochrane Database Syst Rev. 2018;(5):CD000146.
  128. Anthenelli RM, Benowitz NL, West R, et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch (EAGLES). Lancet. 2016;387(10037):2507-2520.
  129. Taylor GMJ, Lindson N, Farley A, et al. Smoking cessation for improving mental health. Cochrane Database Syst Rev. 2021;(3):CD013522.
  130. Benowitz NL. Nicotine addiction. N Engl J Med. 2010;362(24):2295-2303.
  131. Le Foll B, Piper ME, Fowler CD, et al. Tobacco and nicotine use. Nat Rev Dis Primers. 2022;8(1):19.
  132. Zangen A, Moshe H, Martinez D, et al. Repetitive deep TMS for smoking cessation: multicenter double-blind RCT. World Psychiatry. 2021;20(3):397-404.
  133. Bolívar HA, Klemperer EM, Coleman SRM, et al. Contingency management for patients receiving medication for opioid use disorder / substance use: systematic review and meta-analysis. JAMA Psychiatry. 2021;78(10):1092-1102. PMID: 34233346.PMID 34233346 (abre em nova aba)
  134. Vocci FJ, Montoya ID. Psychological treatments for stimulant misuse, comparing and contrasting. Curr Opin Psychiatry. 2009;22(3):263-268.
  135. Rawson RA, Gonzales R, Brethen P. Treatment of methamphetamine use disorders: an update. J Subst Abuse Treat. 2002;23(2):145-150.
  136. Trivedi MH, Walker R, Ling W, et al. Bupropion and naltrexone in methamphetamine use disorder (ADAPT-2). N Engl J Med. 2021;384(2):140-153.
  137. Kampman KM. The treatment of cocaine use disorder. Sci Adv. 2019;5(10):eaax1532.
  138. Volkow ND, Wang GJ, Fowler JS, et al. Decreased dopamine D2 receptor availability associated with reduced frontal metabolism in cocaine abusers (ver item 73).
  139. Ronsley C, Nolan S, Knight R, et al. Treatment of stimulant use disorder: systematic review of reviews. PLoS One. 2020;15(6):e0234809.
  140. Volkow ND, Baler RD, Compton WM, Weiss SRB. Adverse health effects of marijuana use. N Engl J Med. 2014;370(23):2219-2227.
  141. Hall W, Degenhardt L. Adverse health effects of non-medical cannabis use. Lancet. 2009;374(9698):1383-1391.
  142. Di Forti M, Quattrone D, Freeman TP, et al. The contribution of cannabis use to variation in incidence of psychotic disorder (EU-GEI). Lancet Psychiatry. 2019;6(5):427-436.
  143. Lopez-Quintero C, Pérez de los Cobos J, Hasin DS, et al. Probability and predictors of transition from first use to dependence on nicotine, alcohol, cannabis, and cocaine. Drug Alcohol Depend. 2011;115(1-2):120-130.
  144. Meier MH, Caspi A, Ambler A, et al. Persistent cannabis users show neuropsychological decline from childhood to midlife. PNAS. 2012;109(40):E2657-E2664.
  145. Connor JP, Stjepanović D, Le Foll B, et al. Cannabis use and cannabis use disorder. Nat Rev Dis Primers. 2021;7(1):16.
  146. Gorelick DA. Pharmacological treatment of cannabis-related disorders: a narrative review. Curr Pharm Des. 2016;22(42):6409-6419.
  147. Potenza MN. The neurobiology of pathological gambling and drug addiction: an overview and new findings. Philos Trans R Soc B. 2008;363(1507):3181-3189.
  148. Grant JE, Potenza MN, Weinstein A, Gorelick DA. Introduction to behavioral addictions. Am J Drug Alcohol Abuse. 2010;36(5):233-241.
  149. Robbins TW, Clark L. Behavioral addictions. Curr Opin Neurobiol. 2015;30:66-72.
  150. Brand M, Young KS, Laier C, et al. Integrating psychological and neurobiological considerations regarding internet-use disorders (I-PACE model). Neurosci Biobehav Rev. 2016;71:252-266.
  151. Kuss DJ, Griffiths MD. Internet and gaming addiction: a systematic literature review of neuroimaging studies. Brain Sci. 2012;2(3):347-374.
  152. Petry NM, Zajac K, Ginley MK. Behavioral addictions as mental disorders: to be or not to be? Annu Rev Clin Psychol. 2018;14:399-423.
  153. Billieux J, Schimmenti A, Khazaal Y, et al. Are we overpathologizing everyday life? A tenable blueprint for behavioral addiction research. J Behav Addict. 2015;4(3):119-123.
  154. Yau YHC, Potenza MN. Gambling disorder and other behavioral addictions: recognition and treatment. Harv Rev Psychiatry. 2015;23(2):134-146.
  155. Brewer JA, Potenza MN. The neurobiology and genetics of impulse control disorders: relationships to drug addictions. Biochem Pharmacol. 2008;75(1):63-75.
  156. Alter A. Irresistible: the rise of addictive technology and the business of keeping us hooked. Penguin Press; 2017.
  157. Gearhardt AN, Corbin WR, Brownell KD. Preliminary validation of the Yale Food Addiction Scale. Appetite. 2009;52(2):430-436.
  158. Schulte EM, Avena NM, Gearhardt AN. Which foods may be addictive? The roles of processing, fat content, and glycemic load. PLoS One. 2015;10(2):e0117959.
  159. McElroy SL, Hudson JI, Mitchell JE, et al. Efficacy and safety of lisdexamfetamine for treatment of binge-eating disorder. JAMA Psychiatry. 2015;72(3):235-246.
  160. Frayling TM, Timpson NJ, Weedon MN, et al. A common variant in FTO is associated with body mass index and predisposes to obesity. Science. 2007;316(5826):889-894.
  161. Volkow ND, Wang GJ, Baler RD. Reward, dopamine and the control of food intake: implications for obesity. Trends Cogn Sci. 2011;15(1):37-46.
  162. Gearhardt AN, DiFeliceantonio AG. Highly processed foods can be considered addictive substances based on established scientific criteria. Addiction. 2023;118(4):589-598.
  163. Farr OM, Sofopoulos M, Tsoukas MA, et al. GLP-1 receptors exist in the brain and GLP-1 agonists modulate CNS reward/appetite circuits. Diabetologia. 2016;59(5):954-965.
  164. Klausen MK, Jensen ME, Møller M, et al. Exenatide once weekly for alcohol use disorder: RCT. JCI Insight. 2022;7(19):e159863.
  165. Miller WR, Rollnick S. Motivational interviewing: helping people change. 3rd ed. Guilford Press; 2013.
  166. Prochaska JO, DiClemente CC. Stages and processes of self-change of smoking: toward an integrative model of change. J Consult Clin Psychol. 1983;51(3):390-395.
  167. Marlatt GA, Gordon JR. Relapse prevention: maintenance strategies in the treatment of addictive behaviors. Guilford Press; 1985.
  168. Larimer ME, Palmer RS, Marlatt GA. Relapse prevention: an overview of Marlatt's cognitive-behavioral model. Alcohol Res Health. 1999;23(2):151-160.
  169. Higgins ST, Budney AJ, Bickel WK, et al. Incentives improve outcome in outpatient behavioral treatment of cocaine dependence. Arch Gen Psychiatry. 1994;51(7):568-576.
  170. Bowen S, Witkiewitz K, Clifasefi SL, et al. Relative efficacy of mindfulness-based relapse prevention, standard relapse prevention, and treatment as usual: RCT. JAMA Psychiatry. 2014;71(5):547-556.
  171. Project MATCH Research Group. Matching alcoholism treatments to client heterogeneity: Project MATCH posttreatment drinking outcomes. J Stud Alcohol. 1997;58(1):7-29.
  172. Magill M, Ray LA. Cognitive-behavioral treatment with adult alcohol and illicit drug users: meta-analysis. J Stud Alcohol Drugs. 2009;70(4):516-527.
  173. Smedslund G, Berg RC, Hammerstrøm KT, et al. Motivational interviewing for substance abuse. Cochrane Database Syst Rev. 2011;(5):CD008063.
  174. Lussier JP, Heil SH, Mongeon JA, et al. A meta-analysis of voucher-based reinforcement therapy for substance use disorders. Addiction. 2006;101(2):192-203.
  175. DiClemente CC, Prochaska JO. Toward a comprehensive, transtheoretical model of change. In: Treating Addictive Behaviors. 1998.
  176. Witkiewitz K, Marlatt GA. Relapse prevention for alcohol and drug problems: that was Zen, this is Tao. Am Psychol. 2004;59(4):224-235.
  177. Bogenschutz MP, Ross S, Bhatt S, et al. Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in alcohol use disorder: RCT. JAMA Psychiatry. 2022;79(10):953-962.
  178. Johnson MW, Garcia-Romeu A, Griffiths RR. Long-term follow-up of psilocybin-facilitated smoking cessation. Am J Drug Alcohol Abuse. 2017;43(1):55-60.
  179. Krupitsky E, Burakov A, Romanova T, et al. Ketamine psychotherapy for heroin addiction. J Subst Abuse Treat. 2002;23(4):273-283.
  180. Mahoney JJ, Hanlon CA, Marshalek PJ, et al. Transcranial magnetic stimulation and deep brain stimulation in substance use disorders. J Neurol Sci. 2020;418:117149.
  181. Luigjes J, Segrave R, de Joode N, et al. Efficacy of invasive and non-invasive brain modulation in addiction: systematic review. Neuropsychol Rev. 2019;29(1):116-138.
  182. Müller UJ, Voges J, Steiner J, et al. Deep brain stimulation of the nucleus accumbens for the treatment of addiction. Ann N Y Acad Sci. 2013;1282:119-128.
  183. DiVito AJ, Leger RF. Psychedelics as an emerging novel intervention in the treatment of substance use disorder: a review. Mol Biol Rep. 2020;47(12):9791-9799.
  184. Autry AE, Adachi M, Nosyreva E, et al. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses (BDNF-mTOR mechanism). Nature. 2011;475(7354):91-95.
  185. Treadway MT, Zald DH. Reconsidering anhedonia in depression: lessons from translational neuroscience. Neurosci Biobehav Rev. 2011;35(3):537-555.
  186. Pizzagalli DA. Depression, stress, and anhedonia: toward a synthesis and integrated model. Annu Rev Clin Psychol. 2014;10:393-423.
  187. Serretti A. Anhedonia: current and future treatments. PCN Reports. 2025. (acervo: PMC11930767)
  188. Anhedonia is associated with a specific depression profile and poor antidepressant response. Int J Neuropsychopharmacol. (acervo: PMC11630035).
  189. Der-Avakian A, Markou A. The neurobiology of anhedonia and other reward-related deficits. Trends Neurosci. 2012;35(1):68-77.
  190. Whitton AE, Treadway MT, Pizzagalli DA. Reward processing dysfunction in major depression, bipolar disorder and schizophrenia. Curr Opin Psychiatry. 2015;28(1):7-12.
  191. Husain M, Roiser JP. Neuroscience of apathy and anhedonia: a transdiagnostic approach. Nat Rev Neurosci. 2018;19(8):470-484.
  192. Steinberg L. A dual systems model of adolescent risk-taking. Dev Psychobiol. 2010;52(3):216-224.
  193. Casey BJ, Jones RM, Hare TA. The adolescent brain. Ann N Y Acad Sci. 2008;1124:111-126.
  194. Romer D, Reyna VF, Satterthwaite TD. Beyond stereotypes of adolescent risk taking: placing the adolescent brain in developmental context. Dev Cogn Neurosci. 2017;27:19-34.
  195. Moffitt TE, Arseneault L, Belsky D, et al. A gradient of childhood self-control predicts health, wealth, and public safety. PNAS. 2011;108(7):2693-2698.
  196. Whiteside SP, Lynam DR. The Five Factor Model and impulsivity: using a structural model of personality to understand impulsivity (UPPS). Pers Individ Dif. 2001;30(4):669-689.
  197. Patton JH, Stanford MS, Barratt ES. Factor structure of the Barratt Impulsiveness Scale (BIS-11). J Clin Psychol. 1995;51(6):768-774.
  198. Verdejo-García A, Lawrence AJ, Clark L. Impulsivity as a vulnerability marker for substance-use disorders. Neurosci Biobehav Rev. 2008;32(4):777-810.
  199. American College of Lifestyle Medicine. Lifestyle medicine: the six pillars. 2021. (base do pilar — ver Biblioteca Sono §13 e Nutrição §15 do acervo)
  200. Wang D, Wang Y, Wang Y, et al. Impact of physical exercise on substance use disorders: a meta-analysis. PLoS One. 2014;9(10):e110728.
  201. Linke SE, Ussher M. Exercise-based treatments for substance use disorders: evidence, theory, and practicality. Am J Drug Alcohol Abuse. 2015;41(1):7-15.
  202. Smith MA, Lynch WJ. Exercise as a potential treatment for drug abuse: evidence from preclinical studies. Front Psychiatry. 2012;3:82.
  203. Kelly JF, Humphreys K, Ferri M. Alcoholics Anonymous and other 12-step programs for alcohol use disorder. Cochrane Database Syst Rev. 2020;(3):CD012880.
  204. Ryan RM, Deci EL. Self-determination theory and the facilitation of intrinsic motivation, social development, and well-being. Am Psychol. 2000;55(1):68-78.
  205. GBD 2016 Alcohol and Drug Use Collaborators. The global burden of disease attributable to alcohol and drug use. Lancet Psychiatry. 2018;5(12):987-1012.
  206. Degenhardt L, Charlson F, Ferrari A, et al. The global burden of disease attributable to alcohol and drug use in 195 countries. Lancet Psychiatry. 2018.
  207. Henderson M, Harvey SB, Øverland S, et al. Work and common psychiatric disorders. J R Soc Med. 2011;104(5):198-207.
  208. Marchand A, Demers A, Durand P. Does work really cause distress? The contribution of occupational structure and work organization. Soc Sci Med. 2005;61(1):1-14.
  209. World Health Organization. ICD-11: burn-out as an occupational phenomenon. 2019.
  210. Brasil. Decreto nº 3.048/1999, Anexo II — Lista de doenças relacionadas ao trabalho. (verificar teor real antes de citar — GRP-NR01)

Conexões

26 referências · 0 com link direto

  1. Holt-Lunstad J, Smith TB, Layton JB. Social relationships and mortality risk: a meta-analytic review. PLoS Medicine. 2010;7(7):e1000316.
  2. Holt-Lunstad J, Smith TB, Baker M, Harris T, Stephenson D. Loneliness and social isolation as risk factors for mortality: a meta-analytic review. Perspect Psychol Sci. 2015;10(2):227–237.
  3. Berkman LF, Syme SL. Social networks, host resistance, and mortality: a nine-year follow-up study of Alameda County residents. Am J Epidemiol. 1979;109(2):186–204.
  4. House JS, Landis KR, Umberson D. Social relationships and health. Science. 1988;241(4865):540–545.
  5. Office of the U.S. Surgeon General. Our Epidemic of Loneliness and Isolation. 2023.
  6. Cacioppo JT, Hawkley LC. Loneliness. In: Handbook of Individual Differences in Social Behavior. (modelo evolutivo)
  7. Cacioppo JT, Cacioppo S. Loneliness in the modern age: an evolutionary theory of loneliness (ETL). Adv Exp Soc Psychol. 2018.
  8. Cole SW et al. Loneliness, eudaimonia, and the human conserved transcriptional response to adversity. Psychoneuroendocrinology. 2015;62:11–17.
  9. Masi CM, Chen HY, Hawkley LC, Cacioppo JT. A meta-analysis of interventions to reduce loneliness. Pers Soc Psychol Rev. 2011;15(3):219–266.
  10. Cohen S, Wills TA. Stress, social support, and the buffering hypothesis. Psychol Bull. 1985;98(2):310–357.
  11. Kiecolt-Glaser JK et al. Hostile marital interactions, proinflammatory cytokine production, and wound healing. Arch Gen Psychiatry. 2005.
  12. Feldman R. The neurobiology of human attachments. Trends Cogn Sci. 2017.
  13. Walum H et al. Genetic variation in the vasopressin receptor 1a gene (AVPR1A) associates with pair-bonding behavior in humans. PNAS. 2008;105(37):14153–14156.
  14. McGlone F, Wessberg J, Olausson H. Discriminative and affective touch: sensing and feeling. Neuron. 2014.
  15. Beckes L, Coan JA. Social baseline theory: the role of social proximity in emotion and economy of action. Soc Personal Psychol Compass. 2011;5(12):976–988.
  16. Eisenberger NI, Lieberman MD, Williams KD. Does rejection hurt? An fMRI study of social exclusion. Science. 2003;302(5643):290–292.
  17. Dunbar RIM. The social brain hypothesis and human evolution (30 anos). Ann Hum Biol. 2024.
  18. Jetten J, Haslam C, Haslam SA (eds). The Social Cure: Identity, Health and Well-Being. Psychology Press; 2012.
  19. Haslam C et al. Advancing the social identity approach to health and well-being: progressing the social cure research agenda. Eur J Soc Psychol. 2017.
  20. Hill PL, Turiano NA. Purpose in life as a predictor of mortality across adulthood. Psychol Sci. 2014;25(7):1482–1486.
  21. Way BM, Taylor SE, et al. Are genetic variations in OXTR, AVPR1A, and CD38 important to social integration? Two large U.S. cohorts. Psychoneuroendocrinology. (PMC3864016)
  22. Gong P et al. Revisiting the impact of OXTR rs53576 on empathy: a population study and meta-analysis. Psychoneuroendocrinology. 2017.
  23. Livingston G et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020;396:413–446.
  24. Meta-análise de solidão e risco de demência (>600.000 indivíduos). Nature Mental Health. 2024.
  25. Análises cross-lagged solidão ⇄ depressão (HRS, adultos 50+). PMC.
  26. Revisões sistemáticas de social prescribing / link workers (NHS). Br J Gen Pract. 2023–2025.

Propósito

52 referências · 42 com link direto

  1. ALIMUJIANG, A. et al. Association between life purpose and mortality among US adults older than 50 years. JAMA Network Open, v. 2, n. 5, e194270, 2019. DOI: 10.1001/jamanetworkopen.2019.4270. Disponível em: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2734064. Acesso em: 3 jul. 2026.DOI 10.1001/jamanetworkopen.2019.4270 (abre em nova aba)
  2. ANTONOVSKY, A. Unraveling the mystery of health: how people manage stress and stay well. San Francisco: Jossey-Bass, 1987.
  3. BALBONI, T. A.; VANDERWEELE, T. J.; DOAN-SOARES, S. D. et al. Spirituality in serious illness and health. JAMA, v. 328, n. 2, p. 184-197, 2022. DOI: 10.1001/jama.2022.11086. Disponível em: https://jamanetwork.com/journals/jama/article-abstract/2794049. Acesso em: 3 jul. 2026.DOI 10.1001/jama.2022.11086 (abre em nova aba)
  4. BAUMEISTER, R. F. Meanings of life. New York: Guilford Press, 1991.
  5. BOREHAM, I. D.; SCHUTTE, N. S. The relationship between purpose in life and depression and anxiety: a meta-analysis. Journal of Clinical Psychology, v. 79, n. 12, 2023. DOI: 10.1002/jclp.23576. Disponível em: https://onlinelibrary.wiley.com/doi/10.1002/jclp.23576. Acesso em: 3 jul. 2026.DOI 10.1002/jclp.23576 (abre em nova aba)
  6. BOYLE, P. A.; BUCHMAN, A. S.; BARNES, L. L.; BENNETT, D. A. Effect of a purpose in life on risk of incident Alzheimer disease and mild cognitive impairment in community-dwelling older persons. Archives of General Psychiatry, v. 67, n. 3, p. 304-310, 2010. DOI: 10.1001/archgenpsychiatry.2009.208. Disponível em: https://pmc.ncbi.nlm.nih.gov/articles/PMC2897172/. Acesso em: 3 jul. 2026.DOI 10.1001/archgenpsychiatry.2009.208 (abre em nova aba)
  7. BOYLE, P. A.; BUCHMAN, A. S.; WILSON, R. S.; YU, L.; SCHNEIDER, J. A.; BENNETT, D. A. Effect of purpose in life on the relation between Alzheimer disease pathologic changes on cognitive function in advanced age. Archives of General Psychiatry, v. 69, n. 5, p. 499-505, 2012. DOI: 10.1001/archgenpsychiatry.2011.1487. Disponível em: https://jamanetwork.com/journals/jamapsychiatry/fullarticle/1151486. Acesso em: 3 jul. 2026.DOI 10.1001/archgenpsychiatry.2011.1487 (abre em nova aba)
  8. BREITBART, W. et al. Pilot randomized controlled trial of individual meaning-centered psychotherapy for patients with advanced cancer. Journal of Clinical Oncology, v. 30, n. 12, p. 1304-1309, 2012. DOI: 10.1200/JCO.2011.36.2517. Disponível em: https://pubmed.ncbi.nlm.nih.gov/22370330/. Acesso em: 3 jul. 2026.DOI 10.1200/JCO.2011.36.2517 (abre em nova aba)
  9. BREITBART, W. et al. Individual meaning-centered psychotherapy for the treatment of psychological and existential distress: a randomized controlled trial in patients with advanced cancer. Cancer, v. 124, n. 15, 2018. DOI: 10.1002/cncr.31539. Disponível em: https://acsjournals.onlinelibrary.wiley.com/doi/abs/10.1002/cncr.31539. Acesso em: 3 jul. 2026.DOI 10.1002/cncr.31539 (abre em nova aba)
  10. BROWN, J. M.; STEIN, J. S. Putting prospection into practice: methodological considerations in the use of episodic future thinking to reduce delay discounting and maladaptive health behaviors. Frontiers in Public Health, v. 10, art. 1020171, 2022. DOI: 10.3389/fpubh.2022.1020171. Disponível em: https://www.frontiersin.org/journals/public-health/articles/10.3389/fpubh.2022.1020171/full. Acesso em: 3 jul. 2026.DOI 10.3389/fpubh.2022.1020171 (abre em nova aba)
  11. BUCKNER, R. L.; ANDREWS-HANNA, J. R.; SCHACTER, D. L. The brain's default network: anatomy, function, and relevance to disease. Annals of the New York Academy of Sciences, v. 1124, p. 1-38, 2008. DOI: 10.1196/annals.1440.011.DOI 10.1196/annals.1440.011 (abre em nova aba)
  12. CASPI, A. et al. The p factor: one general psychopathology factor in the structure of psychiatric disorders? Clinical Psychological Science, v. 2, n. 2, p. 119-137, 2014. DOI: 10.1177/2167702613497473.DOI 10.1177/2167702613497473 (abre em nova aba)
  13. CHEN, Y.; KIM, E. S.; VANDERWEELE, T. J. Religious-service attendance and subsequent health and well-being throughout adulthood: evidence from three prospective cohorts. International Journal of Epidemiology, v. 49, n. 6, p. 2030-2040, 2020. DOI: 10.1093/ije/dyaa120. Disponível em: https://pmc.ncbi.nlm.nih.gov/articles/PMC7203669/. Acesso em: 3 jul. 2026.DOI 10.1093/ije/dyaa120 (abre em nova aba)
  14. COHEN, R.; BAVISHI, C.; ROZANSKI, A. Purpose in life and its relationship to all-cause mortality and cardiovascular events: a meta-analysis. Psychosomatic Medicine, v. 78, n. 2, p. 122-133, 2016. DOI: 10.1097/PSY.0000000000000274. Disponível em: https://pubmed.ncbi.nlm.nih.gov/26630073/. Acesso em: 3 jul. 2026.DOI 10.1097/PSY.0000000000000274 (abre em nova aba)
  15. DAMÁSIO, B. F.; KOLLER, S. H. Meaning in Life Questionnaire: adaptation process and psychometric properties of the Brazilian version. Revista Latinoamericana de Psicología, v. 47, n. 3, p. 185-195, 2015. DOI: 10.1016/j.rlp.2015.06.004. Disponível em: https://www.sciencedirect.com/science/article/pii/S0120053415000163. Acesso em: 3 jul. 2026.DOI 10.1016/j.rlp.2015.06.004 (abre em nova aba)
  16. D'ARGEMBEAU, A. On the role of the ventromedial prefrontal cortex in self-processing: the valuation hypothesis. Frontiers in Human Neuroscience, v. 7, art. 372, 2013. DOI: 10.3389/fnhum.2013.00372. Disponível em: https://www.frontiersin.org/journals/human-neuroscience/articles/10.3389/fnhum.2013.00372/full. Acesso em: 3 jul. 2026.DOI 10.3389/fnhum.2013.00372 (abre em nova aba)
  17. DECI, E. L.; RYAN, R. M. Self-determination theory: basic psychological needs in motivation, development, and wellness. New York: Guilford Press, 2017.
  18. ERSNER-HERSHFIELD, H.; WIMMER, G. E.; KNUTSON, B. Saving for the future self: neural measures of future self-continuity predict temporal discounting. Social Cognitive and Affective Neuroscience, v. 4, n. 1, p. 85-92, 2009. DOI: 10.1093/scan/nsn042. Disponível em: https://academic.oup.com/scan/article-abstract/4/1/85/1613040. Acesso em: 3 jul. 2026.DOI 10.1093/scan/nsn042 (abre em nova aba)
  19. FISCHER, I. C.; NICHTER, B.; FELDMAN, D. B.; NA, P. J.; TSAI, J.; HARPAZ-ROTEM, I.; SCHULENBERG, S. E.; PIETRZAK, R. H. Purpose in life protects against the development of suicidal thoughts and behaviors in U.S. veterans without a history of suicidality: a 10-year, nationally representative, longitudinal study. Journal of Affective Disorders, v. 340, p. 551-554, 2023. DOI: 10.1016/j.jad.2023.08.040. Disponível em: https://www.sciencedirect.com/science/article/abs/pii/S0165032723010169. Acesso em: 3 jul. 2026.DOI 10.1016/j.jad.2023.08.040 (abre em nova aba)
  20. FRANKL, V. E. Em busca de sentido: um psicólogo no campo de concentração. Petrópolis: Vozes; São Leopoldo: Sinodal, [1946].
  21. FRANKL, V. E. A vontade de sentido: fundamentos e aplicações da logoterapia. São Paulo: Paulus, [1969].
  22. GILBERT, D. T.; WILSON, T. D. Prospection: experiencing the future. Science, v. 317, n. 5843, p. 1351-1354, 2007. DOI: 10.1126/science.1144161.DOI 10.1126/science.1144161 (abre em nova aba)
  23. GLOSTER, A. T. et al. The empirical status of acceptance and commitment therapy: a review of meta-analyses. Journal of Contextual Behavioral Science, v. 18, p. 181-192, 2020. DOI: 10.1016/j.jcbs.2020.09.009. Disponível em: https://www.sciencedirect.com/science/article/abs/pii/S2212144720301769. Acesso em: 3 jul. 2026.DOI 10.1016/j.jcbs.2020.09.009 (abre em nova aba)
  24. HAYES, S. C.; STROSAHL, K. D.; WILSON, K. G. Acceptance and commitment therapy: the process and practice of mindful change. 2. ed. New York: Guilford Press, 2012.
  25. HELLER, A. S. et al. Sustained striatal activity predicts eudaimonic well-being and cortisol output. Psychological Science, v. 24, n. 11, p. 2191-2200, 2013. DOI: 10.1177/0956797613490744. Disponível em: https://journals.sagepub.com/doi/10.1177/0956797613490744. Acesso em: 3 jul. 2026.DOI 10.1177/0956797613490744 (abre em nova aba)
  26. HILL, P. L.; TURIANO, N. A. Purpose in life as a predictor of mortality across adulthood. Psychological Science, v. 25, n. 7, p. 1482-1486, 2014. DOI: 10.1177/0956797614531799. Disponível em: https://pmc.ncbi.nlm.nih.gov/articles/PMC4224996/. Acesso em: 3 jul. 2026.DOI 10.1177/0956797614531799 (abre em nova aba)
  27. INSEL, T. et al. Research Domain Criteria (RDoC): toward a new classification framework for research on mental disorders. American Journal of Psychiatry, v. 167, n. 7, p. 748-751, 2010. DOI: 10.1176/appi.ajp.2010.09091379.DOI 10.1176/appi.ajp.2010.09091379 (abre em nova aba)
  28. JOINER, T. E. Why people die by suicide. Cambridge, MA: Harvard University Press, 2005.
  29. KIM, E. S.; CHEN, Y.; NAKAMURA, J. S.; RYFF, C. D.; VANDERWEELE, T. J. Sense of purpose in life and subsequent physical, behavioral, and psychosocial health: an outcome-wide approach. American Journal of Health Promotion, v. 36, n. 1, p. 137-147, 2022. DOI: 10.1177/08901171211038545. Disponível em: https://pmc.ncbi.nlm.nih.gov/articles/PMC8669210/. Acesso em: 3 jul. 2026.DOI 10.1177/08901171211038545 (abre em nova aba)
  30. KLONSKY, E. D.; MAY, A. M. The three-step theory (3ST): a new theory of suicide rooted in the “ideation-to-action” framework. International Journal of Cognitive Therapy, v. 8, n. 2, p. 114-129, 2015. DOI: 10.1521/ijct.2015.8.2.114.DOI 10.1521/ijct.2015.8.2.114 (abre em nova aba)
  31. KOENIG, H. G.; KING, D. E.; CARSON, V. B. Handbook of Religion and Health. 2. ed. Oxford: Oxford University Press, 2012.
  32. LI, S.; LUO, H.; HUANG, F.; WANG, Y.; YIP, P. S. F. Associations between meaning in life and suicidal ideation in young people: a systematic review and meta-analysis. Children and Youth Services Review, v. 158, art. 107477, 2024. DOI: 10.1016/j.childyouth.2024.107477. Disponível em: https://www.sciencedirect.com/science/article/abs/pii/S0190740924000495. Acesso em: 3 jul. 2026.DOI 10.1016/j.childyouth.2024.107477 (abre em nova aba)
  33. MARTIN, R. A. et al. Purpose in life predicts treatment outcome among adult cocaine abusers in treatment. Journal of Substance Abuse Treatment, v. 40, n. 2, p. 183-188, 2011. DOI: 10.1016/j.jsat.2010.10.002. Disponível em: https://pmc.ncbi.nlm.nih.gov/articles/PMC3031725/. Acesso em: 3 jul. 2026.DOI 10.1016/j.jsat.2010.10.002 (abre em nova aba)
  34. McKNIGHT, P. E.; KASHDAN, T. B. Purpose in life as a system that creates and sustains health and well-being: an integrative, testable theory. Review of General Psychology, v. 13, n. 3, p. 242-251, 2009. DOI: 10.1037/a0017152.DOI 10.1037/a0017152 (abre em nova aba)
  35. O'CONNOR, R. C.; KIRTLEY, O. J. The integrated motivational-volitional model of suicidal behaviour. Philosophical Transactions of the Royal Society B, v. 373, n. 1754, art. 20170268, 2018. DOI: 10.1098/rstb.2017.0268. Disponível em: https://pubmed.ncbi.nlm.nih.gov/30012735/. Acesso em: 3 jul. 2026.DOI 10.1098/rstb.2017.0268 (abre em nova aba)
  36. RYFF, C. D. Happiness is everything, or is it? Explorations on the meaning of psychological well-being. Journal of Personality and Social Psychology, v. 57, n. 6, p. 1069-1081, 1989. DOI: 10.1037/0022-3514.57.6.1069.DOI 10.1037/0022-3514.57.6.1069 (abre em nova aba)
  37. RYFF, C. D. Purposeful engagement, healthy aging, and the brain. Current Behavioral Neuroscience Reports, v. 4, n. 4, 2017. DOI: 10.1007/s40473-017-0127-4. Disponível em: https://pmc.ncbi.nlm.nih.gov/articles/PMC5438094/. Acesso em: 3 jul. 2026.DOI 10.1007/s40473-017-0127-4 (abre em nova aba)
  38. RYFF, C. D.; KEYES, C. L. M. The structure of psychological well-being revisited. Journal of Personality and Social Psychology, v. 69, n. 4, p. 719-727, 1995. DOI: 10.1037/0022-3514.69.4.719.DOI 10.1037/0022-3514.69.4.719 (abre em nova aba)
  39. SCHACTER, D. L.; ADDIS, D. R.; BUCKNER, R. L. Remembering the past to imagine the future: the prospective brain. Nature Reviews Neuroscience, v. 8, n. 9, p. 657-661, 2007. DOI: 10.1038/nrn2213.DOI 10.1038/nrn2213 (abre em nova aba)
  40. SELIGMAN, M. E. P. Flourish: a visionary new understanding of happiness and well-being. New York: Free Press, 2011.
  41. SHAYGAN, M. et al. The effect of mobile-based logotherapy on depression, suicidal ideation, and hopelessness in patients with major depressive disorder: a mixed-methods study. Scientific Reports, v. 13, art. 15828, 2023. DOI: 10.1038/s41598-023-43051-8. Disponível em: https://www.nature.com/articles/s41598-023-43051-8. Acesso em: 3 jul. 2026.DOI 10.1038/s41598-023-43051-8 (abre em nova aba)
  42. SHEN, B. et al. Effectiveness of meaning-centered interventions on anxiety and depressive symptoms, sense of meaning, and quality of life in patients with advanced cancer: a meta-analysis of randomized controlled trials. Supportive Care in Cancer, v. 33, n. 1, 2025. DOI: 10.1007/s00520-024-09075-0.DOI 10.1007/s00520-024-09075-0 (abre em nova aba)
  43. SNYDER, C. R. The psychology of hope: you can get there from here. New York: Free Press, 1994.
  44. SONE, T. et al. Sense of life worth living (ikigai) and mortality in Japan: Ohsaki study. Psychosomatic Medicine, v. 70, n. 6, p. 709-715, 2008. DOI: 10.1097/PSY.0b013e31817e7e64.DOI 10.1097/PSY.0b013e31817e7e64 (abre em nova aba)
  45. STEGER, M. F. et al. The Meaning in Life Questionnaire: assessing the presence of and search for meaning in life. Journal of Counseling Psychology, v. 53, n. 1, p. 80-93, 2006. DOI: 10.1037/0022-0167.53.1.80.DOI 10.1037/0022-0167.53.1.80 (abre em nova aba)
  46. SUTIN, A. R. et al. Purpose in life and stress: an individual-participant meta-analysis of 16 samples. Journal of Affective Disorders, v. 345, p. 378-385, 2024. DOI: 10.1016/j.jad.2023.10.122. Disponível em: https://www.sciencedirect.com/science/article/abs/pii/S0165032723013459. Acesso em: 3 jul. 2026.DOI 10.1016/j.jad.2023.10.122 (abre em nova aba)
  47. SUTIN, A. R.; LUCHETTI, M.; STEPHAN, Y.; KARAKOSE, S.; MANSOR, N.; TERRACCIANO, A. Purpose in life and depressive symptoms: an individual-participant meta-analysis of >500.000 participants across six world regions. Journal of Affective Disorders, v. 398, art. 120881, 2026. DOI: 10.1016/j.jad.2025.120881. Disponível em: https://pmc.ncbi.nlm.nih.gov/articles/PMC12823043/. Acesso em: 3 jul. 2026.DOI 10.1016/j.jad.2025.120881 (abre em nova aba)
  48. TANNO, K. et al. Associations of ikigai as a positive psychological factor with all-cause mortality and cause-specific mortality among middle-aged and elderly Japanese people: findings from the Japan Collaborative Cohort Study. Journal of Psychosomatic Research, v. 67, n. 1, p. 67-75, 2009. DOI: 10.1016/j.jpsychores.2008.10.018. Disponível em: https://pubmed.ncbi.nlm.nih.gov/19539820/. Acesso em: 3 jul. 2026.DOI 10.1016/j.jpsychores.2008.10.018 (abre em nova aba)
  49. VAN DEN BRINK, B. et al. Religiosity, spirituality, meaning-making and suicidality in psychiatric patients and suicide attempters: a systematic review and meta-analysis. Harvard Review of Psychiatry, v. 32, n. 6, p. 195-206, 2024. DOI: 10.1097/HRP.0000000000000409. Disponível em: https://pubmed.ncbi.nlm.nih.gov/39514867/. Acesso em: 3 jul. 2026.DOI 10.1097/HRP.0000000000000409 (abre em nova aba)
  50. VANDERWEELE, T. J.; LI, S.; TSAI, A. C.; KAWACHI, I. Association between religious service attendance and lower suicide rates among US women. JAMA Psychiatry, v. 73, n. 8, p. 845-851, 2016. DOI: 10.1001/jamapsychiatry.2016.1243. Disponível em: https://pubmed.ncbi.nlm.nih.gov/27367927/. Acesso em: 3 jul. 2026.DOI 10.1001/jamapsychiatry.2016.1243 (abre em nova aba)
  51. VANDERWEELE, T. J. On the promotion of human flourishing. Proceedings of the National Academy of Sciences, v. 114, n. 31, p. 8148-8156, 2017. DOI: 10.1073/pnas.1702996114. Disponível em: https://www.pnas.org/doi/10.1073/pnas.1702996114. Acesso em: 3 jul. 2026.DOI 10.1073/pnas.1702996114 (abre em nova aba)
  52. VOS, J.; VITALI, D. The effects of psychological meaning-centered therapies on quality of life and psychological stress: a meta-analysis. Palliative & Supportive Care, v. 16, n. 5, p. 608-632, 2018. DOI: 10.1017/S1478951517000931. Disponível em: https://pubmed.ncbi.nlm.nih.gov/30246682/. Acesso em: 3 jul. 2026.DOI 10.1017/S1478951517000931 (abre em nova aba)

Em caso de dúvidas, fale com a gente.

Entre em contato conosco →